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CHAPTER – I 
INTRODUCTION 
ORAL CONTROLLED DRUG DELIVERY SYSTEMS 
Drug delivery is the method or process of administering a pharmaceutical compound 
to achieve a therapeutic effect in humans or animals.18 Drug delivery technologies are the 
formulation technologies that modify drug release profile, absorption, distribution and 
elimination for the benefit of improving product efficacy and safety, as well as patient 
convenience and compliance.[3] 
Routes of administration 3  
 Enteral. 
 Topical. 
 Parenteral. 
Enteral drug delivery: 
It includes peroral i.e, 
 Gastro-intestinal 
 Sub-lingual 
 Rectal 
Topical drug delivery: 
It includes skin, eyes or other membranes. 
 Intranasal 
 Inhalational 
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 Intravaginal 
 Transdermal 
Parenteral drug delivery: 
It includes all routes of administration through or under one or more layers of skin. 
 Intramuscular  
 Subcutaneous 
 Intravenous 
 
The most preferred route of drug administration for systemic delivery of drugs is 
orally.2 More than 50% of drug delivery systems available in the market are oral drug 
delivery systems. These systems have the obvious advantages of case of administration and 
patient acceptance. Several oral drug delivery technologies have come and gone, and new 
systems still emerge even today. 
 One would always like to have ideal drug delivery systems that will possess two 
main properties,35  
1. It will be a single dose for the whole duration of treatment,  
2. It will deliver the active drug directly at the site of action.  
 
 It offers advantages like, 48 
 Ease of administration 
 Patient compliance 
 Flexibility in formulation 
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THE CHALLENGE: 
Most of the marketed products currently available are immediate release products. To 
achieve and maintain the concentration of an administered drug within therapeutically 
effective range, it is often necessary to take drug dosage several times and this result in a 
fluctuating drug level in plasma.1,2,3  
 
  THE CONTROLLED RELEASE:2,3 
 
 Controlled drug delivery is one which delivers the drug at a predetermined rate, for 
locally or systemically, for a specified period of time. 
 Continuous oral delivery of drugs at predictable & reproducible kinetics for 
predetermined period throughout the course of GIT. 
 
There are many benefits offered by controlled drug delivery systems. For example, 
sustained release technologies allow prolonged delivery of a therapeutic dose, thus reducing 
the number of times that a patient needs to take their medication while maintaining a steady 
state of drug in the bloodstream, and time-delayed release introduces a lag time before dose 
release, providing pulsatile delivery of drug to specific sites, such as the colon, or at a 
specific time. Temporal control of drug release has particular advantages in the treatment of 
disorders that demonstrate a circadian pattern, such as cardiovascular disorders, asthma, 
anxiety and hypercholesterolemia. In such cases, the development of controlled-release 
formulations that deliver the payload at an optimal time can greatly enhance the therapeutic 
effects of the drug and reduce the dose required. 
CHAPTER – I INTRODUCTION 
 
4 
 
 
Fig: 1 
 
ORAL CONTROLLED RELEASE FORMULATIONS1: 
Oral route has been the commonly selected and most convenient for the drug delivery. 
Oral route of administration has more attention in the pharmaceutical field because of the 
more flexibility in the designing of dosage form than routes drug delivery.  
Most of the oral controlled drug delivery systems rely on diffusion, dissolution or 
combination of both mechanisms, to release the drug in a controlled manner to the 
Gastrointestinal Tract (GIT).  
Novel oral drug delivery systems are broadly classified in to two categories as they 
may controlled release dosage forms as well as targeting dosage forms. General controlled 
manner in the GIT for systemic uptake and no particular area of GIT specified. In contrast, 
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targeted preparations are releasing the drug in a specified area or tissue of the GIT (e.g. colon 
specific drug delivery systems). 
Targeting systems are either releasing drug in controlled manner or in one burst at the 
specific area.4 The goal of a targeted oral drug delivery system (TODDS) is to achieve better 
therapeutics success compared to conventional dosage form. This can be achieved by 
improving the pharmacokinetic profile, patient convenience and compliance in therapy, some 
of the advantages of TODDS are: 
 Reduced dosing frequency 
 Better patient convenience and compliance 
 Reduced GI side effects and other toxic effects. 
 Less fluctuating plasma drug level 
 More uniform drug effect 
 Less total dose 
 Better stability of the drug. 
On the other hand TODDS suffer from a number of potential disadvantages: 
o Higher cost 
o Relatively poor in vitro-in vivo correlation 
o Possible dose dumping  
o Reduced potential for dose change or withdrawal in the event of toxicity 
Targeting of drugs through oral route involves control of time of release or location of 
release. On the basis of environmental, anatomical and physiological factors these drug 
delivery system can be classified with respect to target site as follows: 
 Systems targeted to stomach/duodenum 
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 Systems targeted to small intestine 
 Systems targeted to large intestine/colon 
 Systems targeted to lymphatic. 
ORAL DIFFUSION-CONTROLLED SYSTEMS5:      
The basic concepts of oral controlled release dosage forms can be defined based on 
release-profile characteristic or the underlying release- controlling mechanism. Two distinct 
drug release profiles, extended and delayed release, are achievable, and they can be used in 
various combinations to provide the desired release rate. Three delivery systems dominate 
today’s market of oral CR products: 
 Matrix systems. 
 reservoir  systems and 
 osmotic systems. 
             Release mechanisms from these dosage forms, diffusion plays a key role in both 
matrix and reservoir systems, whereas osmotic pressure is the predominant mechanism of 
drug release from osmotic systems and could also play a role in a reservoir system. 
Matrix systems 
A matrix system consists of active and inactive ingredients that are homogeneously 
mixed in the dosage form. Matrix systems divide into two categories, based on rate-
controlling materials. 
 Hydrophobic matrix systems 
 Hydrophilic matrix systems  
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Hydrophobic matrix systems: 
This is the only system where use of a polymer is not essential to provide controlled 
drug release, although insoluble polymers have been used. As the term suggests, the primary 
rate-controlling components of a hydrophobic matrix are water insoluble in nature. These 
ingredients include waxes, glycerides, fatty acids, and polymeric materials such as ethyl 
cellulose and methacrylate copolymers. To modulate drug release, it is necessary to 
incorporate soluble ingredients such as lactose into the formulation. 
The presence of insoluble ingredients in the formulations helps to maintain the 
physical dimension of a hydrophobic matrix during drug release. Diffusion of the active form 
from the system is the release mechanism. Very often, pores form within a hydrophobic 
matrix as a result of the release of the active ingredient. Hydrophobic matrix systems 
generally are not suitable for insoluble drugs because the concentration gradient is too low to 
render drug release. 
Hydrophilic matrix systems:5 
The primary rate-controlling ingredients of a hydrophilic matrix are polymers that 
would swell on contact with the aqueous solution and form a gel layer on the surface of the 
system. 
Drugs release from hydrophilic matrices is by polymer dissolution (erosion) and 
diffusion of drug molecules across the gel layer have been identified as the rate-controlling 
mechanisms.  
The model semi empirical “exponent equation” has been used widely to differentiate 
the contributions of both mechanisms: 
                                                       Qt =ktn 
Where Qt is amount Q in time t, n is a diffusion exponent, and k is a kinetic constant. If 
diffusion dominates polymer erosion, the value of n would approach 0.5. On the other hand, 
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for erosion-controlled formulations, n would approach the value of unity. Under an 
“anomalous” condition, the value of n falls in between 0.5 and 1 when both diffusion and 
erosion play roles.  
More recently, a “spaghetti” model (fig.2) for a swollen matrix was developed to 
provide mechanistic understanding of the complex release process. This model treats polymer 
erosion as diffusion of polymer across a “diffusion layer” adjacent to the gel layer. Thus two 
competitive diffusion processes contribute to overall drug release: diffusion of polymer 
across the diffusion layer and diffusion of drug across the gel layer. 
 
 
 
                                                                 Fig: 2 
 
 For very soluble compounds, diffusion of drug molecules is the dominant mechanism 
of release, and the role of polymer erosion is limited in modulating drug release. Thus, 
developing a hydrophilic matrix for highly soluble drugs that requires prolonged release (e.g., 
>12 h) can be challenging. On the other hand, release of less soluble drugs from hydrophilic 
matrices is expected to be slow because both polymer dissolution and drug diffusion play key 
roles.  
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Classification of oral controlled drug delivery system  
1. Continuous release system  
1. Dissolution controlled release system 
2. Diffusion controlled release system  
3. Diffusion and dissolution controlled release system.  
4. ion exchange resin drug complexes  
5. slow dissolving salt and complexes  
6. pH independent formulations. 
7. Osmotic pressure controlled systems 
8. Hydrodynamic pressure controlled systems.  
 
      2.    Delayed transit and continuous release systems  
1. Altered density system. 
2.   Mucoadhesive system. 
3. Size based systems. 
        3.    Delayed Release system  
1. Intestinal release system. 
2. Colonic release system. 
 
Factors influencing the design and performance of controlled drug delivery system 1, 4 ,5 
 
1. Biopharmaceutic characteristic of the drug  
1. Molecular weight of the drug  
2. Aqueous solubility of the drug  
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3. Apparent partition coefficient  
4. Drug Pka and ionization physiological PH  
5. Drug stability  
6. Mechanism and site of absorption  
7. Route of administration. 
2. Pharmacokinetic characteristic of the drug  
1. Absorption rate  
2. Elimination half life  
3. Rate of metabolism  
4. Dosage form index  
3. Pharmacodynamic characteristic of the drug  
1. Therapeutic range  
2. Therapeutic index  
3. Plasma–concentration–response relationship  
Advantages of controlled drug delivery systems:  
 
1. Improved patient convenience and compliance  
2. Reduction in fluctuation in steady state levels. 
3. Increased safety margin of high potency drugs. 
4. Reduction in dose. 
5. Reduction in health care cost.  
6. Total dose is low. 
7. Reduced GI side effects.  
8.  Reduced dosing frequency.    
9. Better patient acceptance and compliance.  
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10.  Less fluctuation at plasma drug levels.  
11. More uniform drug effect  
12.  Improved efficacy/safety ratio.  
13. Dose dumping.   
14. Reduced potential for accurate dose adjustment. 
15. Need of additional patient education. 
Disadvantages of controlled drug delivery systems  
 
1. Decreased systemic availability. 
2. Poor invitro-invivo correlations. 
3. Chances of dose dumping. 
4. Dose withdrawal is not possible. 
5. Higher cost of formulation. 
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CHAPTER - II 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM  
 
Gastro retentive Drug Delivery System 27, 28 
One of the "holy grails" in oral drug delivery is to develop gastric retention platforms 
for long-term (ranging from 6 to 24 hours) delivery of drugs by oral administration. 
Gastroretentive dosage forms are drug delivery systems which remain in the stomach for an 
extended period of time and allow both spatial and time control of drug liberation. Basically 
gastroretentive systems swells following ingestion and is retained in the stomach for a 
number of hours, while it continuously releases the incorporated drug at a controlled rate to 
preferred absorption sites in the upper intestinal tract. Their application can be advantageous 
in the case of drugs absorbed mainly from the upper part of GIT or are unstable in the 
medium of distal intestine. 
 
 Gastrointestinal Tract 
 Anatomy of the gastrointestinal tract: 
The gastrointestinal tract is divided into three main regions namely: 
 Stomach.  
 Small intestine (Duodenum, Jejunum and Ileum).             
  Large intestine. 
 The GIT is a muscular tube, from the mouth to the anus, which functions to take in 
nutrients and eliminate waste by secretion, motility, digestion, absorption and excretion, 
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which are known as physiological processes. The stomach is a J-shaped enlargement of the 
GIT which is divided into 4 anatomical regions: 
 cardia  
 fundus  
 body  
 antrum3 (Fig.1).  
The main function of the stomach is to store and mix food with gastric secretions 
before emptying its load (chyme) through the pyloric sphincter and into the small intestine at 
a controlled rate suitable for digestion and absorption. During empty state, the stomach 
occupies a volume of about 50 ml, but this may increase to as much as 1 litre when full. The 
walls of the GIT, from stomach to large intestine, have the same basic arrangement of  
tissues, the different layers, from outside to inside, comprising serosa, intermuscular plane, 
longitudinal muscle, submucosa, circular muscle, lamina propria, muscularis mucosae, and 
epithelium. In addition to longitudinal and circular muscle, the stomach has a third muscle 
layer known as the "oblique muscle layer", which is situated in the proximal stomach, 
branching over the fundus and higher regions of the gastric body. The different                            
smooth muscle layers are responsible for performing the motor functions                                                          
of the GIT, i.e. gastric emptying and intestinal transit.                                         
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Fig: 3 Anatomy of the gastrointestinal tract 
 
Basic gastrointestinal tract physiology 
 
The stomach is divided into 3 regions anatomically: fundus, body, and antrum 
pylorus. The proximal part is the fundus and the body acts as a reservoir for 
undigested material, where as the antrum is the main site for mixing motions and acts as a 
pump for gastric emptying by propelling actions. Gastric emptying occurs during fasting as 
well as fed states but the pattern of motility is distinct in the 2 states. During the fasting state 
an interdigestive series of electrical events take place, which cycle through both stomach and 
intestine every 2 to 3 hours. This is called the interdigestive myloelectric cycle or migrating 
myloelectric cycle (MMC), which is divided into following 4 phases3 (Fig.2). 
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Fig: 4 Schematic representation of Interdigestive Motility 
 Phase I: This period lasts about 30 to 60 minutes with no contractions.  
 Phase II: This period consists of intermittent contractions that increase gradually in 
intensity as the phase progresses, and it lasts about 20 to 40 minutes. Gastric 
discharge of fluid and very small particles begins later in this phase.  
 Phase III: This is a short period of intense distal and proximal gastric contractions (4-
5 contractions per minute) lasting about 10 to 20 minutes these contractions, also 
known as ‘‘house-keeper wave,’’ sweep gastric contents down the small Intestine.  
 Phase IV: This is a short transitory period of about 0 to 5 minutes, and the 
contractions dissipate between the last part of phase III and quiescence of phase 
Need for gastroretention 3, 25 
• Drugs that are absorbed from the proximal part of the gastrointestinal tract (GIT). 
• Drugs that are less soluble or that degrade at the alkaline pH. 
•  Drugs that are absorbed due to variable gastric emptying time. 
•  Local or sustained drug delivery to the stomach and proximal small intestine to treat 
certain conditions. 
• Treatment of peptic ulcers caused by H.Pylori infections 63.  
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 Formulation considerations for GRDDS4 
 It must be effective retention in the stomach to suit for the clinical demand.  
 It must be convenient for intake to facilitate patient compliance.  
 It must have sufficient drug loading capacity and control drug release profile.  
 It must have full degradation and evacuation of the system once the drug release is 
over.  
 It should not have effect on gastric motility including emptying pattern.  
 It should not have other local adverse effects. 
 Certain types of drugs can benefit from using gastro retentive devices5 
 Drugs with a narrow absorption window 68.  
 Drugs acting locally in the stomach.  
 Drugs those are primarily absorbed in the stomach.  
 Drugs those are poorly soluble at an alkaline PH.  
 Drugs absorbed rapidly from the GI tract.  
 Drugs those degrade in the colon. 
 Drugs those are unsuitable for gastro retentive drug delivery systems6 
 Drugs that have very limited acid solubility e.g. Phenytoin etc.  
 Drugs that suffer instability in the gastric environment e.g. Erythromycin etc.  
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. 
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Factors affecting gastric retention5 
Various factors that affect the bioavailability of dosage form and efficacy of the gastro 
retentive system are:        
 Density: Gastric retention time (GRT) is a function of buoyancy of dosage form that 
is dependent on the density.  
 Size: Dosage form units with a diameter of more than 7.5 mm are reported to have an 
increased GRT compared with those with a diameter of 9.9 mm.  
 Shape: Tetrahedron and ring shaped devices with a flexural modulus of 48 and 22.5 
kilo pounds per square inch (KSI) are reported to have better GRT 90% to 
100% retention at 24 hours compared with other shapes.  
 Single or Multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to failure of 
units, allow co-administration of units with different release profiles or containing 
incompatible substances and permit a larger margin of safety against dosage form 
failure compared with single unit dosage forms. 
 Fed or unfed state: Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) that 
occurs every 1.5 to 2hrs. The MMC sweeps undigested material from the stomach 
and, if the timing of administration of the formulation coincides with that of the 
MMC, the GRT of the unit can be expected to be very short. However, in the fed 
state, MMC is delayed and GRT is considerably longer.  
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 Nature of meal: Feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate 
and prolonging drug release.  
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is high in 
proteins and fats.  
 Frequency of feed: The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC.  
 Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their 
age and race matched female counterparts (4.6±1.2 hours), regardless of the weight, 
height and body surface).  
 Age: Elderly people, especially those over 70, have a significantly longer GRT.  
 Posture: GRT can vary between supine and upright ambulatory states of the patient.  
 Concomitant drug administration: Anticholinergics like atropine, propantheline, 
opiates like codeine and prokinetic agents like Metoclopramide and Cisapride, can 
affect floating time.        
 Biological factors: Diabetes and Crohn’s disease etc. 
Approaches to Gastric retention 59 
Various approaches for gastro retentive drug delivery systems are:  
(A)  Floating drug delivery 47 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach, 5 (Fig.3), for a prolonged period of time, 
without affecting the gastric emptying rate and the drug is released slowly at a desired rate 
from the system, results in an increase in the gastric residence time and a better control of 
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fluctuations in the plasma drug concentrations and after complete release of the drug, the 
residual system is emptied from the stomach. 
 
Fig: 5 Graphic of the buoyant tablet which is less dense than the stomach fluid and 
therefore remains in the fundus. 
(B) Bio/Muco-adhesive systems 
  Bio/muco-adhesive systems, 5 bind to the gastric epithelial cell surface or mucin, 
which extends the GRT of drug delivery system in the stomach. The surface epithelial 
adhesive properties of mucin have been well recognized and applied to the development of 
GRDDS based on bio/muco-adhesive polymers. The ability to provide adhesion of a drug 
delivery system to the gastrointestinal wall provides longer residence time in a particular 
organ site, thereby producing an improved effect in terms of local action or systemic effect. 
Binding of polymers to the mucin/epithelial surface can be divided into three categories:   
 
1. Hydration-mediated adhesion: 
Certain hydrophilic polymers tend to imbibe large amount of water and become 
sticky, thereby acquiring bio adhesive properties. 
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2. Bonding-mediated adhesion: 
 
The adhesion of polymers to a mucus/epithelial cell surface involves various bonding 
mechanisms, including physical-mechanical bonding and chemical bonding. Physical-
mechanical bonds can result from the insertion of the adhesive material into the folds or 
crevices of the mucosa. Chemical bonds may be either covalent (primary) or ionic 
(secondary) in nature. Secondary chemical bonds consist of dispersive interactions (i.e., 
Vander Waals interactions) and stronger specific interactions such as hydrogen bonds. The 
hydrophilic functional groups responsible for forming hydrogen bonds are the hydroxyl and 
carboxylic groups. 
 
3. Receptor-mediated adhesion: 
 
Certain polymers bind to specific receptor sites on the cell surfaces, thereby 
enhancing the gastric retention of dosage forms.  
Various investigators have proposed different mucin-polymer interactions, 4 such as: 
• Wetting and swelling of the polymer to permit intimate contact with the biological 
tissue.  
• Interpenetration of bio adhesive polymer chains and entanglement of polymer and 
mucin chains.  
• Formation of weak chemical bonds.  
• Sufficient polymer mobility to allow spreading.  
• Water transport followed by mucosal dehydration (Lehr, 1992; Mortazavi, 1993).  
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The bioadhesive coated system when comes in contact with the mucus layer, various 
non-specific (Vander Waals, hydrogen bonding and/or hydrophobic interactions) or specific 
interactions occurs between the complimentary structures and these interactions last only 
until the turnover process of mucin and the drug delivery system should release its drug 
contents during this limited adhesion time, in order for a bio adhesive system to be 
successful. 
 
Fig: 6 Bioadhesive systems 
 
(C)  Raft-forming systems: 61 
These systems, 9 contain gel-forming solution (e.g. sodium alginate solution 
containing carbonates or bicarbonates), which on contact with the gastric contents, swells and 
forms a viscous cohesive gel containing entrapped CO2 bubbles, releases drug slowly in 
stomach by forming the raft layer on the top of gastric fluid (Fig.4). These formulations 
contain antacids such as calcium carbonate or aluminium hydroxide to reduce gastric acidity.  
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Fig: 7 Barrier formed by a raft-forming system 
 
(D) Swelling and expanding systems: 60 
A dosage form in the stomach will withstand gastric transit if it is bigger than the 
pyloric sphincter, also the dosage form must be small enough to be swallowed, and must not 
cause gastric obstruction either singly or by accumulation. Thus, their configurations are 
required to develop an expandable system in order to prolong the gastric retention time 
(GRT), 9: 
 
1) A small configuration for oral intake. 
2) An expanded gastroretentive form. 
3) A final small form enabling evacuation following drug release from the device. Swellable 
systems, 9 (Fig.7), are also retained in the gastro intestinal tract (GIT) due to their mechanical 
properties. The swelling is usually results from osmotic absorption of water and the dosage 
form is small enough to be swallowed by the gastric fluid.   
• Expandable systems, 9 have some drawbacks like problematical storage of much 
easily hydrolysable, biodegradable polymers relatively short-lived mechanical shape 
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memory for the unfolding system most difficult to industrialize and not cost effective. 
Again, permanent retention of rigid, large single-unit expandable drug delivery 
dosage forms may cause brief obstruction, intestinal adhesion and gastropathy. 
 
 
Fig: 8  Drug release from swellable systems 
 
Thus, gastro retentivity is improved by the combination of substantial dimension with high 
rigidity of dosage form to withstand peristalsis and mechanical contractility of the stomach. 
Unfoldable and swellable systems have been investigated and recently tried to develop an 
effective gastro retentive drug delivery.  
Unfoldable and swellable systems have been investigated and recently tried to 
develop an effective gastro retentive drug delivery. 
Unfoldable systems, 9 are made of biodegradable polymers. They are available in different 
geometric forms (Fig.6), like tetrahedron, ring or planner membrane (4 - label disc or 4 - 
limbed cross form) of bioerodible polymer compressed within a capsule which extends in the 
stomach.   
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Fig : 9 Different geometric forms of unfoldable systems. 
 
(E)  Superporous Hydrogels: 
Conventional hydrogels, with pore size ranging between 10 nm and 10 µm has very 
slow process of water absorption and require several hours to reach an equilibrium state 
during which premature evacuation of the dosage form may occur while the superporous 
hydrogel (Fig.8), having average pore size (>100 µm), swell to equilibrium size within a 
minute, due to rapid water uptake by capillary wetting through numerous interconnected 
open pores. Moreover they swell to a large size (swelling ratio 100 or more) and are intended 
to have sufficient mechanical strength to withstand pressure by gastric contractions. This is 
achieved by a co- formulation of a hydrophilic particulate material, Ac-Di-Sol 
(crosscarmellose sodium). 4 
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Fig:10 On the left, Superporous Hydrogels in its dry (a) and water-swollen (b) state. On 
the right, schematic illustration of the transit of Superporous Hydrogel. 
 
(F) Magnetic systems: 
This approach is based on the simple principle that the dosage form contains a small 
internal magnet, and a magnet placed on the abdomen over the position of the stomach to 
enhance the gastric retention time (GRT). 4 The external magnet must be positioned with a 
degree of high precision that might compromise patient compliance. 
   
 (G) Self-unfolding systems: 
 
The self-unfolding systems are capable of mechanically increasing in size relative to 
the initial dimensions. This increase prevents the system from passing through the pylorus 
CHAPTER – II GASTRORETENTIVE 
DRUG DELIVERY 
SYSTEM 
 
26 
 
and retains for a prolonged period of time in the stomach. A drug can be either contained in a 
polymeric composition of the gastro retentive system or included as a separate component. 
Several methods,4 were suggested to provide for the self-unfolding effect 
• The use of hydrogels swelling in contact with the gastric juice. 
• Osmotic systems, comprising an osmotic medium in a semi-permeable 
membrane 
• Systems based on low-boiling liquids converting into a gas at the body 
temperature 
 
(H) High density systems: 
These systems with a density of about 3 g/cm3 are retained in the rugae of the stomach 
and are capable of withstanding its peristaltic movements. A density of 2.6-2.8 g/cm3 acts as 
a threshold value after which such systems can be retained in the lower part of the stomach. 
High density formulations include coated pellets. Coating is done by heavy inert material 
such as barium sulphate, zinc oxide, titanium dioxide, iron powder etc. They are retained in 
the antrum of stomach, 5 (Fig.9). 
 
Fig: 11 Graphic of heavy tablet which is denser than the stomach fluid and therefore 
sinks to the antrum 
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Floating drug delivery systems: 56, 64, 53 
 
A floating dosage form is useful for drugs acting locally in the proximal 
gastrointestinal tract. These systems are also useful for drugs that are poorly soluble (or) 
unstable in intestinal fluids. The floating properties of these systems help to retain in the 
stomach for a long time. Various attempts have been made to develop floating systems, 
which float on the gastric contents and release drug molecules for the desired time period. 
After the release of a drug, the remnants of the system are emptied from the stomach.  
 
Based on the mechanism of buoyancy, two different technologies have been used in 
development of floating drug delivery systems. These include: 
 
a) Effervescent system. 
 
b) Non- Effervescent system. 
 
a) Effervescent Systems 
 
Effervescent systems, 5 include use of gas generating agents, carbonates (e.g. Sodium 
bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in the 
formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the system 
and  making it float on the gastric fluid. An alternative is the incorporation  of  matrix 
containing  portion  of  liquid, which produce gas that evaporate at body temperature 
. 
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 Fig: 12 Gas generating systems 
 
These effervescent systems further classified into two types: 
 
1)      Gas generating systems. 
2)      Volatile liquid or vacuum containing systems. 
 
1) Gas generating systems 
A) Tablets: 29 
1. Intragastric single layer floating tablets or Hydrodynamically Balanced System     
(HBS)   
These formulations have bulk density lower than gastric fluids and thus float in the 
stomach that increases the gastric emptying rate for a prolonged period, 5 (Fig.10). These are 
formulated by intimately mixing the gas (CO2) generating agents and the drug within the 
matrix tablet.  The drug is released slowly at a desired rate from the floating system and the 
residual system  is emptied from  the stomach after the complete release of the drug. This 
leads to an increase in the gastric residence time (GRT) and a better                                    
control over fluctuations in plasma drug concentration. 
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Fig 13: Intragastric single layer floating tablet 
 
2. Intragastric bilayer floating tablets  
These are also compressed tablets, 5 containing two layers (Fig.11): 
 Immediate release layer 
  Sustained release layer.   
 
Fig 14: Intragastric bilayer floating tablet 
B) Floating capsules 
These floating capsules, 4 are formulated by filling with a mixture of sodium alginate 
and sodium bicarbonate. The systems float as a result of the generation of CO2 that was 
trapped in the hydrating gel network on exposure to an acidic environment.  
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C) Multiple unit type floating pills 
  These multiple unit type floating pills, 5 are sustained  release pills, known as ‘seeds’, 
which are surrounded by two layers (Fig.12). The outer layer  is of swellable membrane layer 
while the inner layer consists of effervescent agents. This system sinks at once and then it 
forms swollen pills like balloons which float as they have lower density, when it is immersed 
in the dissolution medium at body temperature. The lower density is due to generation and 
entrapment of CO2 within the system. 
 
 
 
 
Fig: 15 (a) A multiple-unit oral floating dosage system. (b) Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and floating; (C) 
dissolution of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) swellable 
layer; (d) expanded swellable membrane layer; (e) surface of water in the beaker 
(370C). 
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D) Floating system with Ion-Exchange resins 
Floating system using bicarbonate loaded ion exchange resin was made by mixing the 
beads with 1M sodium bicarbonate solution, and then the semi-permeable membrane is 
used to surround the loaded beads to avoid sudden loss of CO2. On contact with gastric 
contents an exchange of bicarbonate and chloride ions takes place that results  in generation 
of CO2 that carries beads towards  the top of gastric contents and producing a floating layer 
of resin beads. 4 
 
  
2) Volatile liquid or vacuum containing systems 
            (a)      Intragastric floating gastrointestinal drug delivery system 
This system floats in the stomach because of floatation chamber, which is vacuum or 
filled with a harmless gas or air, while the drug reservoir is encapsulated by a microporous 
compartment, 5 (Fig.13). 
 
Fig: 16 Intragastric floating gastrointestinal drug delivery device 
 
(b)      Inflatable gastrointestinal delivery systems   
These systems are incorporated with an inflatable chamber, which contains liquid 
ether that gasifies at body temperature to inflate the chamber in the stomach. These systems 
are fabricated by loading the inflatable chamber with a drug reservoir, which can be a drug, 
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impregnated polymeric matrix, then encapsulated in a gelatin capsule, 5 (Fig.14). After oral 
administration, the capsule dissolves to release the drug reservoir together with the inflatable 
chamber. The inflatable chamber automatically inflates and retains the drug reservoir 
compartment in the stomach. The drug is released continuously from the reservoir into gastric 
fluid. 
 
Fig: 17 Inflatable gastrointestinal delivery system 
 
c)      Intragastric osmotically controlled drug delivery system 
This system is comprised of an osmotic pressure controlled drug delivery device and 
an inflatable floating support in a biodegradable capsule, 5 (Fig.15). On contact with the 
gastric contents in the stomach, the capsule disintegrates quickly to release the intragastirc 
osmotically controlled drug delivery device. The inflatable support inside forms a hollow 
polymeric bag which contains a liquid that gasifies at body temperature to inflate the bag and 
it is deformable. The osmotic pressure controlled drug delivery device consists of two 
components, osmotically active compartment and a drug reservoir compartment. The drug 
reservoir compartment is enclosed by a pressure responsive collapsible bag, which is 
impermeable to liquid and vapor and has a drug delivery orifice. The osmotically active 
compartment contains an osmotically active salt and is enclosed within a semi-permeable 
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housing. In the stomach, the osmotically active salt present in the osmotically active 
compartment is dissolved by absorbing the water continuously present in the GI fluid through 
the semi-permeable membrane. An osmotic pressure is thus created which acts on the 
collapsible bag and in turn forces the drug reservoir compartment to reduce its volume and 
activate the drug reservoir compartment to reduce its volume and activate the drug release of 
a drug solution formulation through the delivery orifice. The floating support is also made to 
contain a bioerodible plug that erodes after a predetermined time to deflate the support. The 
deflated drug delivery system is then emptied from the stomach. 
 
 
Fig: 18 Intragastric osmotically controlled drug delivery system 
 
b) Non-Effervescent systems 
The Non-Effervescent floating drug delivery systems are based on mechanism of 
swelling of polymer or bioadhesion to mucosal layer in GI tract. The various types of this 
system are: 
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1)      Single layer floating tablets: 
These are formulated by intimate mixing of drug with a gel forming hydrocolloid, that swells 
on contact with gastric fluid and maintain bulk density of less than unity. The air trapped by 
the swollen polymer confers buoyancy to these dosage forms. 5  
 
 2)      Bilayer floating tablets 
        A bilayer tablet contain two layer one immediate release layer which release initial dose                   
from system while the another sustained release layer absorbs gastric fluid, forming an 
impermeable colloidal gel barrier on its surface, and maintain a bulk density of less than unity 
and thereby it remains buoyant in the stomach. 5 
 
3)      Alginate beads 
Multi unit floating dosage forms were developed from freeze dried calcium alginate. 
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping a sodium 
alginate solution into aqueous solution of CaCl2, causing precipitation of calcium alginate 
leading to formation of porous system, which can maintain a floating force for over 12 hours. 
When compared with solid beads, which gave  a short  residence, time of 1 hr, and these 
floating beads gave a prolonged residence time of more than 5.5 hours. 5 
  
4) Hollow microspheres 
Hollow  microspheres (microballons), loaded with drug in their outer polymer shells 
were prepared by a novel emulsion-solvent diffusion  method (Fig.16). The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer was poured into an 
agitated aqueous solution of PVA that was thermally controlled at 400C. The gas phase 
generated  in dispersed polymer droplet by evaporation of dichloromethane formed an 
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internal cavity in microsphere of polymer with drug. The microballons floated 
continuously over  the surface of acidic dissolution media containing surfactant for more than 
12 hours in vitro. 5 
 
 
Fig: 19 Formulation of floating hollow microsphere or microballoon 
 
 
v)  EVALUATION OF FLOATING SYSTEMS 
I.PRELIMINARY EVALUATION: 
a) Buoyancy Lag Time 
It is determined in order to assess the time taken by the dosage form to float on the top of 
the dissolution medium, after it is placed in the medium. These parameters can be 
measured as a part of the dissolution test. 
b) Floating Time 
Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid maintained at 370C. 
The time for which the dosage form continuously floats on the dissolution media is termed 
as floating time. 
c) Specific Gravity / Density 
Density can be determined by the displacement method using Benzene as medium. 
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II:IN-VITRO DISSOLUTION TESTS34.39 
A. In vitro dissolution test is generally done by using USP apparatus with paddle and 
GRDDS is placed normally as for other conventional tablets. But sometimes as the vessel is 
large and paddles are at bottom, there is much lesser paddle force acts on floating dosage 
form which generally floats on surface. As floating dosage form not rotates may not give 
proper result and also not reproducible results. Similar problem occur with swellable dosage 
form, as they are hydrogel may stick to surface of vessel or paddle and gives irreproducible 
results. In order to prevent such problems, various types of modification in dissolution 
assembly made are as follows. 
B. To prevent sticking at vessel or paddle and to improve movement of dosage form, method 
suggested is to keep paddle at surface and not too deep inside dissolution medium. 
C. Floating unit can be made fully submerged, by attaching some small, loose, non reacting 
material, such as few turns of wire helix, around dosage form. However this method can 
inhibit three dimensional swelling of some dosage forms and also affects drug release. 
D. Other modification is to make floating unit fully submerged under ring or mesh assembly 
and paddle is just over ring that gives better force for movement of unit. 
E. Other method suggests placing dosage form between 2 ring/meshes. 
F. In previous methods unit have very small area, which can inhibit 3D swelling of swellable 
units, another method suggest the change in dissolution vessel that is indented at some above 
place from bottom and mesh is place on indented protrusions, this gives more area for dosage 
form. 
G. Inspite of the various modifications done to get the reproducible results, none of them 
showed co-relation with the in-vivo conditions. So a novel dissolution test apparatus with 
modification of Rossett-Rice test Apparatus was proposed.  
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III) IN-VIVO EVALUATION 
a) Radiology 
X-ray is widely used for examination of internal body systems. Barium Sulphate is widely 
used Radio Opaque Marker. So, BaSO4 is incorporated inside dosage form and X-ray 
images are taken at various intervals to view GR. 
b) Scintigraphy 
Similar to X-ray, emitting materials are incorporated into dosage form and then images are 
taken by scintigraphy. Widely used emitting material is 99Tc. 
c) Gastroscopy 
Gastroscopy is peroral endoscopy used with fibre optics or video systems. Gastroscopy is 
used to inspect visually the effect of prolongation in stomach. It can also give the detailed 
evaluation of GRDDS. 
d) Magnetic Marker Monitoring 
In this technique, dosage form is magnetically marked with incorporating iron powder 
inside, and images can be taken by very sensitive bio-magnetic measurement equipment. 
Advantage of this method is that it is radiation less and so not hazardous. 
e) Ultrasonography 
Used sometimes, not used generally because it is not traceable at intestine. 
f) 13C Octanoic Acid Breath Test 
13C Octanoic acid is incorporated into GRDDS. In stomach due to chemical reaction, 
octanoic acid liberates CO2 gas which comes out in breath. The important Carbon atom 
which will come in CO2 is replaced with 13C isotope. So time up to which 13CO2 gas is 
observed. 
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 Advantages of floating drug delivery system5 
• The principle of Hydrodynamically Balanced System (HBS) can be used  for any 
particular medicament or class of medicament. The HBS formulations are not 
restricted to medicaments, which are principally absorbed from  the stomach, since it 
has been found that these are equally efficacious with medicaments which are 
absorbed from the intestine. e.g. Chlorpheniramine maleate. 
• The HBS are advantageous for drugs absorbed through the stomach e.g. ferrous salts 
and for drugs meant for local action in the stomach and treatment of peptic ulcer 
disease e.g. antacids. 
• The efficacy of the medicaments administered utilizing the sustained  release 
principle of HBS has been found to be independent of the site of absorption of the 
particular medicaments. 
• Administration of a prolonged release floating dosage form tablet or capsule will 
result in dissolution of the drug in gastric fluid. After emptying of the stomach 
contents, the dissolved drug is available for absorption in the small intestine, therefore 
it is expected that a drug will be fully absorbed from the floating dosage form if it 
remains in solution form even at alkaline pH of the intestine.  
• Many drugs categorized as once-a-day delivery have been demonstrated  to have  
suboptimal absorption due to dependence on the transit time of the dosage form, 
making traditional extended release development challenging. Therefore, a system 
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designed  for  longer gastric retention  will extend the time within which drug 
absorption can occur in the small intestine.  
• When there is vigorous intestinal movement and a short transit time as might occur in 
certain type of diarrhoea, poor absorption is expected under such circumstances it 
may be advantageous to keep the drug in floating condition in stomach to get a 
relatively better response.  
• Gastric retention will provide advantages such as the delivery of drugs with narrow 
absorption windows in the small intestinal region. 
 Limitations of floating drug delivery system11 
• The floating system requires, sufficiently high level of fluid in the stomach for the 
system  to float, this can be overcome by administering dosage form with a glass full 
of water (200-250 ml) or coating the dosage form with bioadhesive polymer which 
adhere to gastric mucosa.  
• Aspirin and  non steroidal anti-inflammatory drugs are known to cause gastric lesions, 
and  slow  release of such drugs in the stomach is unwanted.  
• Drugs, such as Isosorbide dinitrate, that are absorbed equally throughout the GI tract, 
drugs undergoing first pass metabolism will not benefit from incorporation into a 
gastric retention system.  
• Floating dosage form should not be given to the patients just before going to the bed 
as gastric emptying occurs rapidly when the subject remains in supine posture.  
• Drugs that have stability or solubility problem in gastrointestinal fluid or that irritate 
gastric mucosa are not suitable.  
CHAPTER – II GASTRORETENTIVE 
DRUG DELIVERY 
SYSTEM 
 
40 
 
• Drugs  that have multiple absorption sites or which undergo first pass metabolism 
were not desirable.  
• The single unit floating dosage form is associated with “all or none concept”. This 
problem can be overcome by formulating multiple unit system like floating 
microballons or microspheres.  
 
Applications of floating drug delivery system11 
 
    Sustained drug delivery: 
   Hydrodynamically Balanced System (HBS) type are dosage forms which have bulk 
density less than one, relatively large in size and did not easily pass through pylorus,                     
releases the drug over a prolonged period of time by retaining in the stomach for 
several hours  and by increasing the gastric residence time.  
 Site specific drug delivery: 
Floating drug delivery systems are particularly useful for drugs having specific 
absorption from stomach or proximal part of the small intestine e.g. riboflavin, furosemide 
etc. The absorption of captopril has been found to be site specific, stomach being the major 
site followed by duodenum.  
          Absorption enhancement: 
Drugs that have  poor bioavailability, because of their absorption  is  restricted  to 
upper  GIT are potential candidates  to be formulated as  floating drug delivery systems, 
thereby improving  their  absolute  bioavailability.  
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              Minimized adverse activity at the colon  
Retention of the drug at the stomach (HBS system), minimizes the amount of drug 
that reaches the colon, that prevents the undesirable activities of the drug in colon. This 
Pharmacodynamic aspect provides the rationale for GRDF formulation for betalactam  
antibiotics that are absorbed only from the small intestine, and whose presence in the colon 
leads to the development of microorganism’s resistance. 
Reduction in plasma fluctuations: 
Patients with advanced Parkinson’s disease, experienced pronounced fluctuations in 
symptoms while treatment with standard L-dopa.  A HBS dosage form provided a better 
control of motor fluctuations although its bioavailability was reduced by 50-60% of the 
standard formulation. 
 
Peptic ulcer treatment: 
H. Pylori, causative bacterium for peptic ulcers and chronic gastritis. Patients require 
high concentration of drug, to be maintained at the site of infection that is within the gastric 
mucosa. The floating dosage form due to its floating ability was retained in stomach and 
maintained high concentration of drug in the stomach. A sustained  liquid preparation of  
Ampicillin, using sodium alginate was developed that spreads out and adheres to gastric 
mucosal surfaces and releases the drug continuously. 
 
Suitable for poorly absorbed drugs. 
 Floating drug delivery systems are particularly useful for drugs which are poorly 
soluble or unstable in intestinal fluids and acid stable drugs and for those which undergo 
abrupt changes in their pH-dependent solubility due to pathophysiological conditions of GIT, 
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food and  age,  e.g. floating  system for furosemide lead to potential  treatment of Parkinson’s 
disease. Approximate 30% drug was absorbed after oral administration. 
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CHAPTER – 3 
LITERATURE REVIEW 
1. Rajashree Masareddy et al., developed and evaluated Floating matrix tablets of 
Riboflavin using METHOCEL K4M and Carbopol 971 P. The release studies showed 
that Carbopol showed better controlled release when compared to METHOCEL K4M.  
 
2. Enas M.Elmowafy et al., done a project on Release mechanisms Behind 
Polysaccharides-Based Controlled Release Matrix Tablets of Famotidine for the treatment 
of Hypertension. The work concluded that the matrix integrity, swelling, drug release and 
kinetics depended on the type and composition of polysaccharides.  
 
3. Praneeth kumar et al ., formulated and characterized floating matrix tablets of 
Metoprolol succinate using Gelucire by melt solidification technique. The results 
indicated Gelucire was an appropriate carrier for floating DDS due to its hydrophobicity 
and low density. 
 
4. P.Patel et al., developed a sustained release non-effervescent floating tablets of captopril 
to avoid intestinal degradation and to prolong drug release. Incorporation of hydrophobic 
EC along with hydrophilic polymers yielded good results compared to hydrophilic 
polymers alone. 
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5. Sustained release floating tablets of Acyclovir was formulated and evaluated by Sachin 
Kumar et al., using HPMC K4M, HPMC K100M and sodium alginate. Combinations of 
HPMC grades and sodium alginate yielded controlled release of drugs. 
 
6. The study of Captopril floating tablets using various grades of HPMC by Shwetha 
Sharma et al., suggested that 12 hour gastric residence and prevention of instability in 
intestine could be achieved for the drug by floating DDS. 
 
7. J.A.Raval et al., investigated the effects of formulation parameters on a floating 
controlled DDS of drug by diluents, hardness and low density foam powder. The results 
revealead that HPMC K100 M provided controlled release and 15% foam powder was 
sufficient to achieve desired floating behaviour. 
 
8. Sumit R.Rathi et al., developed a single unit gastro retentive DDS of Famotidine due to 
its shorter half life. The results indicated sodium alginate could be successfully used to 
modify release rates in hydrophilic matrix tablets. 
 
9. V.D.Havaldar et al., studied the influence of different polymers on gastric residence time 
and release rate of Atenolol. The results suggested that the formulations with higher 
swelling indices retarded drug release more than those with lower swelling indices. 
 
10. Gottimukkala jayapal reddy et al., developed and optimized a controlled release DDS 
of Nizatidine to increase its gastric retention time. It was concluded that HPMC K4M 
resulted better controlled release properties compared to SCMC. 
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11. Baljit singh et al., made an attempt to synthesize gastro-retentive floating drug delivery 
system by simultaneous ionotropic gelation of alginate and sterculia gum by using CaCl2 
as cross linker. The beads thus formed have been characterized by scanning electron 
micrographs (SEMs), electron dispersion X-ray analysis (EDAX), Fourier transform 
infrared spectroscopy (FTIR) analysis. The swelling of beads has been carried out as a 
function of various reaction parameters and pH of the swelling media. In addition, in vitro 
release dynamics of anti-ulcer model drug pantoprazole from drug loaded beads in 
different release media has been carried out for the evaluation of the drug release 
mechanism and diffusion coefficients. Release of drug from beads occurred through 
Fickian type diffusion mechanism. 
 
12. Nagalakshmi S. et al., formulated and evaluated floating matrix tablets of Pioglitazone 
HCL by non-effervescent and effervescent techniques. The best formulation was 
identified as that containing HPMC K100 M which exhibited good floating behaviour and 
good controlled release properties. 
 
13. Sivabalan M. et al., formulated and evaluated Hydrodynamically balanced controlled 
DDS of Glipizide. The methodology of factorial design helped in determining the 
relationships between the factors acting on the system and the response of the system. 
The principle of HBS offered a suitable approach to obtain controlled release of Glipizide 
with enhanced bioavailability and reduced dosing frequency. 
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14. Inez Jimenez-Martinez et al., carried out a work on the invitro sustained release of 
captopril from Metolose SH and sodium bicarbonate floating tablets varying the 
proportions of Metolose SH and sodium bicarbonate at two different compaction 
pressures. The increase of the matrix polymer proportion increased the maximum 
hydration volume. 
 
15. Rajesh Kumar Ranga et al., developed and characterized novel gastro retentive floating 
bioadhesive tablets of Glipizide which possess unique combination of floatation and 
bioadhesion properties. The results concluded that floating and bioadhesive tablets of 
glipizide were potential dosage forms due to its prolonged release in stomach as 
compared to conventional dosage forms. 
 
16. Prajapathi S.T. et al., developed floating matrix tablets of Domperidone to prolong the 
gastric residence of drug using HPMC K4M and carbopol 934. From the results it was 
observed that carbopol showed negative effect on floating properties but yielded 
controlled release profiles.  
 
 
17. Ramesh bomma et al., developed floating tablets of norfloxacin to prolong the gastric 
residence time of the drug. The invivo studies revealed that the tablets remained in the 
stomach for 6 hours in fasting human volunteers and indicated that gastric retention was 
increased by floating mechanism and would be a promising approach for delivery of anti 
ulcer drugs. 
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18. Padmavathi j. et al., outlined a systemic approach for designing and developing 
ofloxacin floating tablets to prolong gastric residence time. Various grades of HPMC 
(K4M, K15, and K100M) were used to formulate floating tablets. The results indicated 
HPMC K4M yielded good results comparing to other formulations. 
 
 
19. Anil kumar J. Shinde et at., formulated and evaluated oral floating tablets of Cephalexin 
using hydrophilic polymer HPMC, sodium bicarbonate and citric acid. The results of 
factorial design indicated that high level of HPMC K100M and citric acid favoured 
preparation of controlled release floating tablets of Cephalexin. 
20. Hitesh P. Dalvadi et al., investigated the development and evaluation of gastro retentive 
tablets of Atenolol using various grades of HPMC. The results indicated that the 
formulations containing HPMC K100 M exhibited better retardation of drug release due 
to its swelling properties. 
 
 
21. Vishnu m.patel et al., developed a controlled release Gastroretentive dosage form of 
verapamil hydrochloride using hydrocolloid polymer like carbopol, HPMC                      ( 
K4M,K15M, E15) and Xanthan gum by direct compression technique. Sodium 
bicarbonate was used as gas generating agent. The results showed that tablets containing 
Xanthan gum showed controlled release for 24 hours hence it was the suitable polymer 
for formulation of matrix tablets. 
 
22. Liandong hu et al., prepared floating matrix dosage form for dextromethorphan 
hydrobromide based on gas formation technique. The combination of sodium bicarbonate 
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(18mg) and hexadecanol (18mg) with HPMC K4M was found to achieve optimum invitro 
release and floatability. The tablets maintained controlled release upto 24 hours. 
 
 
23. Arunachalam A. et al., developed a floatable drug delivery system of levofloxacin 
hemihydrates for sustained drug delivery and Gastroretentive property with special 
emphasis on optimization of formulations. It was found that effervescent floating drug 
delivery was a promising approach to achieve buoyancy and the addition of gel forming 
polymer controlled the drug release. 
 
24. Londhe S. et al., developed and evaluated floating DDS with Biphasic release of 
Verapamil hydrochloride. The floating behaviour of drug was studied in rabbit which 
showed gastric residence of 7 hour. 
 
 
25. Ferdous khan MD. et al., prepared and evaluated Gastroretentive floating tablets of 
theophylline using hydrophilic polymers. Sodium bicarbonate and citric acid were used as 
the gas generating agents. It was found that the release rate, extent and mechanisms were 
dependent on the concentration of the polymers and the gas generating agent. The results 
suggested a proper balance of a hydrophilic polymer and the soluble component could 
produce a drug release profile comparable to the theoretical release profile. 
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CHAPTER - 4 
AIM OF THE WORK 
Oral drug administration still remains the preferred route of choice for delivery of 
drugs into systemic circulation. Some drugs have ideal characteristics for good absorption 
throughout the g.i.t while the others present difficulties due to narrow absorption window 
in stomach and proximal gut, stability problems in intestinal fluids, poor solubility in 
intestine or requirement of  local action in the stomach. Rapid and unpredictable gastro 
intestinal transit could result in incomplete drug absorption from the tablet leading to 
diminished efficacy of the administered dose.  
                        Perindopril erbumine {2-Methylpropan-2-amine (2S, 3aS, 7aS)-1-[(2S)-2-
[[(1S)-1-(ethoxycarbonyl) butyl] amino] propanoyl]octahydro - 1 H-indole-2-carboxylate},  a 
newer ACE inhibitor is used in the treatment of stable coronary artery disease and 
hypertension. Since the drug is preferentially absorbed in the proximal small intestine 
(narrow absorption window), the drug displays oral bioavailability problems in conventional 
dosage forms. 
                       An elegant and simple way to improve drug absorption and for releasing the 
drug in a controlled manner is to hold a DDS above the absorption window. Because most 
absorption windows are thought to be located in proximal small intestine, the obvious 
strategy is to hold the formulation in the stomach (i.e., gastro retention). Gastro retention 
can be achieved via intra-gastric floating systems, sedimentation or high density systems, 
swelling or expandable systems, geometry or modified shaped systems and super porous 
hydro gels. 
CHAPTER - 4 AIM 
OF 
THE 
WORK 
 
50 
 
                       High density systems have a technical difficulty in formulating a dosage form 
having a density of 2.4-2.8 kg/cm2, bio-adhesive systems may be dislodged from its site of 
adhesion, expandable systems may expand in oesophagus or intestines or failed to reduce in 
size after drug absorption to permit its transit through intestine for excretion. 
The attractive principle of floating drug delivery system is exploited by the use of 
gel forming polymers such as semi-synthetic derivatives of cellulose along with 
polysaccharides which swells in gastric fluids with a bulk density less than 1. It remains 
buoyant and floats on g.i fluids prolonging GRT. This floating dosage forms are well known 
as hydro-dynamically balanced systems. 
  The present investigation aims to develop floating dosage forms of perindopril 
erbumine by non-effervescent technique using polymers Hydroxy propyl methyl 
cellulose(HPMC) K100M, Methylcellulose(MC), Hydroxy propyl methyl cellulose(HPMC) 
E15 and polysaccharide Xanthan gum(XG) and to evaluate the formulations for invitro and 
invivo studies. 
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CHAPTER - 5 
PLAN OF WORK 
 
STEP-I   
PREFORMULATION STUDIES: 
1. Determination of λmax of Perindopril erbumine in 0.1M HCL. 
2. Calibration curve for the Perindopril erbumine at λmax in 0.1M HCL. 
 
 
STEP-II 
FORMULATION OF FLOATING TABLETS: 
1. Precompression Evaluation. 
2. Preparation of Floating matrix tablets of Perindopril erbumine using different 
concentrations of hydrophilic swellable gel forming polymers                                                                                   
(HPMC K100M, HPMC E15, MC, XG) by using non effervescent technique. 
 
 
STEP-III 
EVALUATION OF FLOATING TABLETS:  
1. Determination of Floating behaviour. 
2. Determination of Swelling Index. 
3. In –vitro release Studies. 
4. Kinetic Analysis of release data. 
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STEP-IV 
Selection of best formulation. 
 
STEP-V 
EVALUATION OF BEST FORMULATION: 
1. Comparison with marketed formulation  
2. Effect of diluents 
3. Stability studies 
4. Invivo studies 
 
STEP-VI 
INTERACTION STUDIES: 
1. Differential scanning calorimetric (DSC) studies 
2.  Fourier Transform Infra Red Spectroscopic (FT-IR) studies  
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CHAPTER – 6 
MATERIALS AND EQUIPMENTS 
 
MATERIALS: 
 
 
Perindopril Erbumine 
 
Gift sample from Orchid Pharma chennai 
 
 
HPMC (different grades) 
 
Gift samples from Orchid Pharma 
 
 
Methyl Cellulose 
 
Gift sample from Orchid Pharma 
 
 
Xanthan Gum 
 
Universal Scientific Appliances 
 
 
Lactose 
 
Universal Scientific Appliances 
 
 
Dicalcium Phosphate 
 
Universal Scientific Appliances 
 
 
Talc 
 
Universal Scientific Appliances 
 
 
Magnesium Stearate 
 
Universal Scientific Appliances 
 
 
Hydrochloric acid 
 
Universal Scientific Appliances 
 
 
All other chemicals were of Analytical Grade. 
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EQUIPMENTS: 
 
 
 
Electronic Weighing Balance 
 
 
A & D Company HR 200  Japan 
 
Single Punch Tablet Compression 
Machine
 
Cadmach 
 
UV Visible Spectrophotometer 
 
Shimadzhu 
 
 
Digital Tablet Dissolution Test Apparatus 
 
Disso 2000, Lab India 
 
 
Friability Test Apparatus 
 
 
Indian Equipment  Corporation 
 
Incubator 
 
 
Tempo Industrial Corporation 
 
Hot air oven 
 
Sico 
 
 
Tablets hardness tester (Monsanto) 
 
Secor India 
 
 
Vernier Caliper 
 
Linker 
 
 
X-ray machine  
 
 
Stallion 20, Elpro International Ltd. 
 
Differential Scanning Calorimeter 
 
DSC 60 Shimadzu 
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DRUG PROFILE
PERINDO
 
Structure:  
                                
                      
 
 
 
Chemical name:  
                 (2S, 3αS, 7αS)-
indolinecarboxylic acid, 1-ethyl ester, compound with tert
  
 
Empirical Formula:  17 
            C19H32N2O5C4H11N. 
  
Description:   
 Nature               : 
 Solubility   :  
            Log P                           :        
       (Octanol/water) 
     Melting point   :         
     Molecular weight  :        
55 
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PRIL ERBUMINE  
 
 
 
1-[(S)-N-[(S)-1-Carboxy-butyl] alanyl] hexahydro
-butylamine (1:1). 
white crystalline powder 
Freely soluble in water, alcohol and chloroform
  2.6 
126 -128°C                     
  441.61 
DRUG 
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Identification: 
208 nm in UV spectrophotometer 
 
Pharmacodynamic properties: 
Perindopril an angiotensin-converting enzyme inhibitor, Perindopril is a prodrug 
which is converted to active metabolite perindoprilat in liver. Perindoprilat the active 
metabolite competes with angiotensin converting enzyme blocking the conversion of 
angiotensin I to angiotensin II. It is a vasoconstrictor and a negative feedback mediator for 
renin activity. Lower concentrations result in decrease in blood pressure and an increase in 
plasma renin. Perindoprilat may also act on kininase II, an enzyme identical to ACE that 
degrades vasodilator bradykinin.  
 
Pharmacokinetic properties: 52 
Absorption 
 Rapid absorption after oral administration. 
 T max is 1 hour for parent compound, 3 to 7 hour for active metabolite. 
 Oral Bioavailability  : 75%  ( Perindopril )   
      25% (Perindoprilat) 
Metabolism 
 30 – 60 % perindopril is converted to active metabolite perindoprilat in liver 
by the enzyme  
Excretion  
 Total Body Clearance:    219 - 362 ml/min. 
 Mean Renal  Clearance:  23.3 - 28.6 ml/min 
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Therapeutic indications 
 Hypertension 
  Stable coronary artery disease 
 
Dose 
 4 mg and 8 mg. Maximum dose is 16 mg/day  
 
Adverse Effects 
 Postural Hypotension 
 Hyperkalemia 
 Cough 
 Angio edema 
 Neutropenia 
 Agranulocytosis 
 Anaphylactoid reactions 
 Nausea 
 Vomiting 
 Dizziness 
 
Drug Interactions: 67 
Diuretics: 
Patients on diuretics and especially those started recently, may occasionally 
experience an excessive reduction of blood pressure after initiation of perindopril erbumine 
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therapy.  The rate and extent of perindopril absorption and elimination are not affected by 
concomitant diuretics. The bioavailability of perindoprilat was reduced by diuretics, however, 
and this was associated with a decrease in plasma ACE inhibition. 
Potassium Supplements and Potassium-Sparing Diuretics: 
Perindopril erbumine may increase serum potassium because of its potential to 
decrease aldosterone production. Use of potassium-sparing diuretics (spironolactone, 
amiloride, triamterene and others), potassium supplements or other drugs capable of 
increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the 
risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should 
be given with caution and the patient's serum potassium should be monitored frequently.  
Lithium: 
Increased serum lithium and symptoms of lithium toxicity have been reported in 
patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be co 
administered with caution and frequent monitoring of serum lithium concentration is 
recommended. Use of a diuretic may further increase the risk of lithium toxicity.  
Digoxin: 
A controlled pharmacokinetic study has shown no effect on plasma digoxin 
concentrations when co administered with perindopril erbumine, but an effect of digoxin on 
the plasma concentration of perindopril/perindoprilat has not been excluded.  
 
Over dose & Treatment: 
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 Symptoms associated with over dosage of ACE inhibitors may include hypotension, 
circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, 
palpitations, bradycardia, dizziness, anxiety, and cough.  The recommended treatment of over 
dosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient 
should be placed in the shock position. If available, treatment with angiotensin II infusion 
and/or intravenous catecholamine may also be considered. Perindopril may be removed from 
the general circulation by haemodialysis. Pacemaker therapy is indicated for therapy-resistant 
bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be 
monitored continuously. 
 
Prescription: 
 Yes 
 
Generic Available: 
 Immediate-release tablets. 
 
Preparations:  
Immediate release tablets – 4mg and 8mg. Maximum dose is 16 mg/day  
 
Storage:  
 It should be stored in a cool, dark and dry place. 
 
Special Precautions 
 Don’t take  potassium supplements without seeking medical advice 
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 Don’t take during pregnancy. 
 
 
Contra-indications 
 Hypersensitivity to Perindopril 
 History of angio edema. 
 During Pregnancy. 
 Hypotension.  
Brand names:  
o ACEON 
o COVERSYL PLUS 
o POVINACE 
o APOPERINDOPRIL 
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POLYMERS AND EXCIPIENTS PROFILE 
HYDROXY PROPYL METHYL CELLULOSE:
Synonym:  
 Hypromellose. 
 Methocel 
 
Structure: 
Empirical formula:  
 It ispartly O-methylated and O
available in several grades 
Molecular weight: 
 10 000 – 1 500 000 
Description:   
 Colour: White or creamy
 Odour: Odorless  
 Taste: Tasteless 
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-(2-hydroxy propylated)cellulose. (PhEur 
depending upon the viscosity and extent of substitution. 
-white fibrous or granular powder. 
 
2005).  It is 
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Solubility: 
 Soluble in cold water, forming a viscous colloidal solution, 
 Practically insoluble in chloroform, ethanol (95 %) and ether, 
  Soluble inmixtures of ethanol and dichloromethane, 
 Soluble in mixtures of water andalcohol. 
 
Functional Category:   
 Coating agent. 
 Film- former. 
 Stabilizing agent. 
 Tablet binder. 
 Viscosity increasing agent. 
 
Typical Viscosity values for 2 % (w/v) aqueous solutions of different viscosity grades of 
HPMC at 20°C 
 
Methocel K100 PremiumLVEP :100 
Methocel K4M Premium  : 4000 
Methocel K15M Premium  : 15000 
Methocel K100M Premium  : 100 000 
Methocel E4M Premium   : 4000 
Methocel F50 Premium   : 50 
Methocel E10M Premium CR  : 10 000 
Methocel E3 Premium LV  : 3 
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Methocel E5 Premium LV   : 5 
Methocel E6 Premium LV   : 6 
Methocel E15 Premium LV   : 15 
Methocel E50 Premium LV   : 50 
Metolose 60SH    : 50, 4000, 10 000 
Metolose 65SH    : 50, 400, 1500, 4000 
Metolose 90SH    : 100, 400, 4000, 15 000  
 
 
 
Storage Conditions: 
 
 It should be stored in a well-closed container, in a cool, dry place. 
 
Handling Precautions: 
 Hypromellose dust may be irritant to the eyes and eye protection is 
recommended 
 Excessive dust generation should be avoided to minimize the risks of 
explosion.  
 Hypromellose is combustible. 
 
REGULATORY STATUS: 
 Included in the FDA inactive ingredients.Recognized by GRAS status. 
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Synonym: 
 Benecel,  
 Metolose 
 
Structure: 
 
 
 
 
 
 
Empirical formula:   
 Long-chain substituted cellulose containing approximately 27 
group in the form of methyl ether
 
Molecular weight:   
 10 000 – 220 000 Dalton.
 
Description:   
 Colour:White, fibrous powder or granules.
 Odour: Practically odorless and
 Taste: Tasteless. 
POLYMERS 
AND 
EXCIPIENTS 
PROFILE
64 
METHYL CELLULOSE: 
– 32 % of the hydroxyl 
. 
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Melting Point: 
 190–200°C. 
 
 
 
Solubility:  
 Practically insoluble in acetone, methanol, chloroform, ethanol (95 %), ether,  
saturated salt solutions, toluene and hot water.   
 In cold water, it swells and disperses slowly to form a clear to opalescent, viscous, 
colloidal dispersion. 
 
Functional Category:   
 Bulk laxative (5.0 – 30.0 %). 
 Emulsifying agent (1.0– 5.0 %), 
 Tablet binder (1.0 – 5.0 %). 
 Tablet Coating (0.5 -5.0 %). 
 Tablet and capsuledisintegrant (2.0 – 10.0 %). 
 
Storage Conditions 
 
 It should be stored in an airtightcontainer in a cool, dry place. 
 
 
Handling Precautions 
 Irritant to theeyes & eye protection should be worn.  
 Methylcellulose is combustible. 
 Spills of the dry powder orsolution should be cleaned up immediately, as the slippery 
filmthat forms can be dangerous. 
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REGULATORY STATUS: 
 Included in the FDA inactive ingredients.Recognized by GRAS status. 
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XANTHAN GUM:51 
Synonyms: 
 Corn sugar gum. 
 Keltrol. 
 Rhodigel. 
 Vanzan NF. 
 Xantural. 
 
Structure: 
 
 
Empirical formula:   
 (C35H49O29) n  
 
Molecular weight:   
 
 2 x106 
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Description: 
 
 Colour: White free flowing fine powder. 
 Odour:Oduorless. 
 Taste: Tasteless. 
 
Melting point: 
 Chars at 270°C. 
 
Solubility: 
 
 Practically insoluble in ethanol and ether;  
 Soluble in cold or warm water. 
 
Functional Category: 
 
 Stabilizing agent. 
  Suspending agent. 
  Viscosity-increasing agent 
 
Storage Conditions: 
 
 It should be stored in a well-closed container. 
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Handling Precautions: 
 
 Observe normal precautions appropriate to the circumstancesand quantity of material 
handled.  
 Eye protection and gloves are recommended. 
 
REGULATORY STATUS: 
 Included in the FDA inactive ingredients.Recognized by GRAS status. 
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LACTOSE: 
Synonym:   
 Lactopress Anhydrous. 
 Lactosum. 
  Milk sugar. 
 
Structure: 
 
 
 
  
Description:   
 White to off-white crystalline particles or powder. 
 
Empirical formula:  
 C12H22O11 
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Molecular weight:  
 342.30 
Solubility:   
 Soluble in water,  
 Sparingly soluble in ethanol (95 %) and  
ether. 
 
Functional Category:  
 Binding agent. 
 Directly compressible excipient. 
 Lyopholization aid. 
 Tablet and capsule filler. 
 
REGULATORY STATUS: 
 Included in the FDA inactive ingredients.Recognized by GRAS status. 
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DIBASIC CALCIUM PHOSPHATE:
Synonym:   
 Calcium orthophosphate. 
  Dicalcium orthophosphate
 Phosphoric acid calciumsalt (
 Secondary calcium phosphate.
 
Structure: 
 
 
Description: 
 
 Colour:White crystalline solid.
 Odour:Oduorless. 
 Taste: Tasteless. 
 
Empirical formula:  
 CaHPO4      
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. 
1: 1). 
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Molecular weight:  
 136.06 
 
Melting point: 
 It does not melt. 
 It decomposes at 425°C to formcalcium pyrophosphate. 
 
Solubility: 
 
 Practically insoluble in ether, ethanol, and water; 
 Soluble in dilute acids. 
 
 
Handling Precautions: 
 
 The fine-milled grades cangenerate nuisance dusts and the use of a respirator or dust 
maskmay be necessary. 
 
Storage Conditions: 
 
 It should be stored in a well-closed container in a dry place. 
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TALC: 
 
Synonyms: 
 Powdered talc. 
  Purified French chalk. 
 Soapstone. 
 
Structure: 
 
 
 
 
Empirical formula: 
 Mg6(Si2O5)4(OH)4 
 
Description: 
 Appearance:Very fine, unctuous, crystalline powder. 
 Colour:White to grayish-white. 
 Odour:Odorless, impalpable. 
 
Solubility: 
 Practically insoluble in dilute acids and alkalis,organic solvents, and water. 
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Storage Conditions: 
 It should be stored in a tightly closed container in a cool and dry place. 
 
Functional Category: 
 Anti caking agent. 
  Glidant. 
 Lubricant. 
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MAGNESIUM STEARATE:
Synonyms: 
 Magnesium octadecanoate. 
 Octadecanoic acid. 
 Magnesium salt. 
 
Structure: 
 
Chemical Name: 
 Octadecanoic acid magnesium salt
Empirical formula: 
 C36H70MgO4 
 
Molecular Weight: 
 591.34 
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Description: 
 It is a very fine powder. 
 
Solubility: 
 Insoluble in ethanol, ether and water. 
 Slightly soluble in warm benzene and warm ethanol95%. 
 
Stability and Storage Conditions: 
 It is stable and should be stored in a well closed container, in a cool, dry place. 
 
Functional Category: 
 Tablet and capsule lubricant. 
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CHAPTER – 9 
EXPERIMENTAL DETAILS 
 
PREPARATION OF DISSOLUTION MEDIUM: 51  
0.1 M HCL: 
                   8.5 ml of hydrochloric acid was dissolved in distilled water and the volume is 
made up to 1L. 
PREPARATION OF CALIBRATION CURVE FOR PERINDOPRIL 
ERBUMINE:  
      To the powder containing 8mg of Perindopril erbumine, 10 ml of distilled water 
was added and the volume was made up to 100 ml with 0.1M HCL.  Dilutions were made to 
get the concentration of 5 to 50 µg/ ml. 10µg/ml  solution was scanned in (UV) 
spectrophotometer to find out the λ max and absorbance of the solution was measured at the 
obtained λ max (208 nm) 17.  
           The calibration graph was plotted by taking the concentration on X axis and 
respective absorbance in Y axis, to get a straight line as per like Beers law. The regression 
value was determined.   
 
PREPARATION OF FLOATING TABLETS: 
   The floating tablets of perindopril erbumine were prepared by direct compression 
technique. Accurately weighed quantities of drug, polymer and lactose were manually mixed 
homogenously. The powder blend was passed through sieve no.22 and lubricated with talc 
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and magnesium stearate.150mg of powder blend was weighed and compressed into 8mm 
biconvex tablets. The formulations were prepared according to the table 2. 
PREFORMULATION STUDIES FOR POWDER BLEND: 
BULK DENSITY: (g/ml) 11, 16 
      Bulk density is the ratio between a given mass of powder and its bulk volume.  
Apparent bulk density was determined by pouring the weighed granules into a graduated 
cylinder via funnel and measuring the volume.  Density was calculated using the formula,  
                                             Mass of the powder                       W 
Bulk Density   =             -------------------------------------   =     ----- 
                                     Bulk volume of the powder                   V0 
 
TAPPED DENSITY:  (g/ml) 15 
      Tapped density is the ratio between a given mass of powder and the constant or 
final volume of powder after tapping.  It was determined by tapping a graduated cylinder 
containing a known mass of granules for a fix number of taps until the powder volume has 
reached a constant value.  The tapped density was computed using the formula, 
                                    
Mass of the powder                                M                            
Tapped Density =   -------------------------------------------------------- =        ----- 
                                     Minimum (tapped) volume of the powder              Vf 
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COMPRESSIBILITY INDEX: (I) 15, 14 
      Compressibility is an important measure that can be obtained from the bulk and 
tapped densities.  The flow ability of the granules was measured by the application of 
compressibility index given by the equation,  
                                  I = [1-Vf / V0] x 100 
                          Where, Vf = volume of the sample after tapping 
                                       V0 = volume before tapping 
 Values of I: 
 Below 15 % indicates to excellent flow characteristics 
 Between 15% - 25% indicates good flow characteristics 
 Above 25 % indicates poor flow ability  
 
ANGLE OF REPOSE: 15,13 
      Angle of Repose is defined as the maximum angle possible between the surface 
of the pile of powder and horizontal plane.  The flow property of the powder blend was 
assessed by determining the angle of repose which was measured by allowing the granules to 
fall over a paper placed on a horizontal surface through a funnel kept at a suitable height (of 
about 6 cm from the paper).  The angle of repose ‘θ’ is given by the formula:   
                       θ = tan -1 (h / r) 
              Where   h = height of the heap 
                                                     r = radius of the base of the heap 
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Angle of Repose Type of flow 
< 20° Excellent 
20°- 30° Good 
30°- 35° Moderate 
35°- 40° Poor 
>  40° Very Poor 
 
 
DRUG CONTENT OF POWDER BLEND: 15 
           10mg drug equivalent of powder blend was dissolved in 10 ml of distilled 
water and the volume was made up to 100 ml with 0.1M HCL. The solution was filtered and 
10ml of filtrate was diluted to 100ml with 0.1M HCL. The absorbance of the resulting 
solution was measured at λ max (208 nm) using UV spectrophotometer and the drug content 
was estimated. 
POST COMPRESSION EVALUATION:  
 
GENERAL APPEARANCE: 
The formulated tablets were evaluated for general appearance viz colour, shape, 
odour, appearance etc. 
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HARDNESS:23 
 Hardness of the tablet was determined using Monsanto hardness tester.  The 
hardness was measured in terms of kg/cm2.  3 tablets were randomly picked from each batch 
and the hardness of the tablets was determined. The mean and standard deviation values were 
calculated for each batch. 
FRIABILITY: 23 ,34 
 Friability was determined using Roche friabilator. 20 tablets were weighed 
accurately and placed in the tumbling apparatus that revolves at 25 rpm dropping the tablets 
through the distance of 6 inches with each revolution.  After 4 min the tablets were reweighed 
and the percentage loss in tablet weight was determined. 
Percentage friability =   Initial weight – Final weight x 100          
                                                                Initial weight 
THICKNESS & DIAMETER: 23 
Thickness of the tablet mainly depends upon the filling, physical properties of 
material to be compressed and compression force. Vernier caliper was used to measure 
tablet thickness and diameter. 3 tablets were randomly picked from each batch and the 
thickness and diameter of the tablets was determined.   
WEIGHT VARIATION: 23, 22,  63 
20 tablets from each formulation were selected randomly, weighed                                                     
individually and the average weight was calculated as per I.P method.  Not more than two 
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tablets should deviate from the percentage as given in IP and none should deviate by more 
than twice that percentage.  
ESTIMATION OF DRUG CONTENT FOR TABLETS: 23,  
10 mg drug equivalent of the powdered formulation was dissolved in sufficient 
amount of distilled water, made up to 100ml with 0.1M HCL and filtered. 10ml of the filtrate 
was made up to 100ml with 0.1M HCL. 10µg/ml solution was prepared from the above 
solution and analyzed for drug content.       
 
IN VITRO BUOYANCY STUDIES: 24 
 
           The tablets were placed in a beaker containing 250 ml of 0.1M HCL 
maintained at 37°C.  The time required for the tablet to rise to the surface was determined as 
floating lag time and the time period up to which the tablet remained floating was 
determined as total floating time. 
 
SWELLING STUDIES: 43, 45, 54, 26 
 
 Swelling is a vital factor to ensure buoyancy and dissolution of floating matrix tablet.  
The swelling of polymers can be measured by their ability to absorb water and swell. 
Swelling studies were carried out in USP type II paddle apparatus containing 900ml of 0.1M 
HCL rotated at 50 rpm kept at 37°C. The tablets were placed in the medium withdrawn at an 
interval of 2, 4, 8, 12 hrs, blotted with filter Paper to remove excess water and weighed. 
      
Swelling index = Final weight – Initial weight / Initial weight x 100 
 
CHAPTER - 9 EXPERIMENTAL 
DETAILS 
 
84 
 
MATRIX INTEGRITY STUDIES: 32 
The relative matrix integrity of the floating tablets was inspected visually. 
 
 IN VITRO RELEASE STUDIES: 33, 42, 10, 40 
 
  In vitro release studies were performed in USP type II paddle apparatus for 12 hours. 
The tablets were placed in the dissolution medium of 900 ml 0.1M HCL in the dissolution 
apparatus. The paddle was rotated at 50 rpm maintained at 37°C. 5 ml samples were 
withdrawn every 15 min for the first hour and every 30 min up to 12 hours. Sink conditions 
were maintained after each sampling. Samples were analyzed at 208 nm using UV 
spectrophotometer. The studies were done in triplicate. The results were shown in table 6. 
 
 
USP Dissolution Test Apparatus  
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KINETIC ANALYSIS: 55, 46 
 
 The In vitro release profiles obtained from the floating tablets were fitted to zero 
order, first order, Higuchi, Hixson Crowell, Korsemeyer & Peppas model kinetics, to find out 
the mechanism of drug release. 
 
Zero Order    :   Qt = Q0 + K0.t 
First Order     :  In Qt = In Q0 + K0.t 
Hixson-Crowell   :  Q01/3 - Qt1/3 + K.t 
Higuchi    :  Q = KH. t1/2 
Korsmeyer - Peppas               :                      Mt / M0 = a.tn 
 Fitness of release profiles to linear equations is assessed by comparing the 
coefficients of determination (r) values. 
For cylinder type of systems, 58, 62 
n < 0.45   : Classical Fickian diffusion 
n=0.45 to 0.89  : Anomalous Non Fickian transport i.e. coupled  
   drug diffusion in the hydrated matrix and  
   polymer relaxation (Indicators of both 
    phenomenon) 
n=0.89   : Case II relaxational release transport - Zero order  
     release (Polymer relaxation or swelling controlled  
     systems) 
n> 0.89            : Super Case II tranpsort . 
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FT-IR STUDIES: 33, 21, 36, 37, 39 
                      The possibility of drug-excipient interactions are further investigated by FT-IR. 
The FT-IR graph of pure drug and combination of drug with excipient are recorded .The 
analysis is performed by using Shimadzu FT-IR Spectrometer. The scanning range is 450-
4000 cm-1 and the resolution is 4cm-1. Samples are prepared in KBr pellets. 
DIFFERENTIAL SCANNING CALORIMETRIC (DSC) STUDIES: 32                     
DSC was performed using Perkin Elmer STA 6000 Thermal Analyzer. The 
instrument was calibrated with indium standard. Accurately weighed (it varies from                                  
3mg-25mg) samples were placed in an open type ceramic sample pans. Thermo grams were 
obtained by heating the sample at a constant heating rate of 8c/minute. A dry purge of Argon 
gas (60ml/min) was used for all runs. Samples were heated from 37-400°C. 
 
SELECTION OF BEST FORMULATION: 
The best formulation was selected depending on the results obtained from floating 
behaviour, swelling index, invitro release studies and kinetic analysis. 
 
COMPARISON WITH MARKETED FORMULATION: 
 The release of the best formulation was compared with the marketed formulation and 
the results are shown in the figure. 
 
EFFECT OF DILUENTS ON THE RELEASE OF BEST 
FORMULATION:  
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The release profile was determined for the best formulation replacing lactose with 
dicalcium phosphate and the results are shown in the figure.  
In vivo X – RAY STUDIES:  58, 66, 49 
The invivo studies approved by Institutional Animal Ethical Committee reference No. 
06444/ E1/4 / 2011 and were performed on healthy male albino rabbit weighing 2-3 kg. The 
animal was fasted overnight but allowed to take water ad libitum. Then 60 ml of 5 % dextrose 
solution was given immediately before administering the tablets (2 tablets – optional) by 
using stomach tube (No. 12 French catheter) and 20 ml syringes.  
The tablets were made opaque by incorporating BaSO4 instead of drug.  The rabbit 
was exposed to X-ray imaging in the abdominal region, and photographs were taken at 0, 2, 
4, 8, 12 hrs after administration of tablet. At hourly intervals 60 ml of 5 % dextrose solution 
was given to maintain optimum fluid level in the stomach. The gastric residence time was 
observed.  
 
STABILITY STUDIES: 65, 20, 57 
To assess the drug and formulation stability, stability studies were done according to 
ICH and WHO guidelines. The best formulation was kept in a stability chamber maintained 
at 27°C and 75 % RH for 3 months.  Samples were analyzed for the drug content, floating 
behavior and other physiochemical parameters periodically.  
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CHAPTER – 10 
RESULTS AND DISCUSSION  
CALIBRATION OF PERINDOPRIL ERBUMINE:  
The λ max of perindopril erbumine was determined by scanning the 10 µg/ml solution 
of the drug using UV spectrophotometer and was found to be 208 nm6 (Fig. 21).  The 
absorbance of the solutions (5 – 50 µg/ml) was measured in UV spectrophotometer at 208 
nm. The correlation coefficient was found to be γ = 0.99945.  The results are given in table 
and the calibration graph of perindopril erbumine is shown in Fig:22 
FORMULATION OF NON-EFFERVESCENT FLOATING TABLETS:   
From the trial studies, the formula was optimized depending on the floating behaviour 
of the tablets and the optimized formula is shown in the table 2.  It was found that the tablets 
showed good floating behaviour at the concentration of 20-75 % of the hydrophilic                
polymers.53 HPMC grades showed better buoyancy at 50% - 80% concentration, while 
Methyl Cellulose (MC) showed good floating behavior at concentrations of 40% - 70% 19.   
The floating lag time was inversely related to the concentration of hydrophilic 
polymers and the formula was optimized accordingly. Xanthan gum (XG) was combined 
with HPMC E15M to over counter the eroding effect of HPMC E15M. 
PRECOMPRESSION STUDIES FOR POWDER BLEND: 
The powder blend of all the formulations was evaluated for the pre-compression 
parameters such as Bulk Density, Tapped Density, Compressibility Index, Angle of Repose, 
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and Percentage Drug Content. The results are tabulated in table 3.  
The Powder blend of all the formulations were found to possess good flow property 
which was indicated by angle of repose 24 - 290,  bulk density 0.38 - 0.42,  tapped density 
0.50 - 0.53 and  percentage  compressibility index 18 – 24 as shown in the Table 3.  
POST COMPRESSION EVALUATION: (12, 16) 
PHYSIOCHEMICAL PROPERTIES: 
The floating matrix tablets were evaluated for various parameters such as General 
Appearance, Hardness, Thickness, Diameter, Friability and Weight variation.  
The formulated tablets were white colour, biconvex, and round shaped.  All the tablets 
were elegant in appearance.  Hardness of all the formulations were found to be in the range of 
3.5 – 4 Kg/cm2, thickness 2.8 – 3 mm, diameter 8 mm, friability less than 1% and weight 
variation within the acceptable limits as per I.P. The results are shown in the table 4 
DRUG CONTENT: 
The percentage drug content of all the formulations was found to be within the limits 
of 99 % - 101 % as per E.P. 
IN VITRO BUOYANCY STUDIES: 
The time required for the tablet to rise to the surface (floating lag time) and the time 
period up to which the tablet remained floating (total floating time) was determined visually. 
Among the four formulations containing HPMC K100M, F1 & F2 floated 
immediately while F3 & F4 showed a lag time of 2 - 3 min. Formulations F5 – F8             
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(containing HPMC E15M alone) had a lag time of 3-4 min, while F13 – F16                 
(containing HPMC E15M & XG) had 7 – 9 min.  This may be due to the denser matrix 
formed by incorporating XG 32. Thus XG had a negative effect on floating properties. 
Formulations F9 – F13 (containing MC) had a floating time of 6 – 8 min.  
Formulations containing HPMC K100M and MC floated more than 12 hours, but in 
the case of HPMC E15 (alone or along with XG) the formulations floated for 8 – 10 hours 
followed by erosion.  
Floating lag time was found to decrease with increasing concentration of polymers. 
The results were shown in the table 5 and fig.23 
 
SWELLING STUDIES: 26, 43, 45, 54 
The results of the swelling studies (table 5) indicated that the swelling index was 
directly proportional to the concentration of polymers (Fig.24) The hydrophilic polymers 
formed a gel layer around the tablet when they contacted water. This is due to the 
penetration of solvent into the free spaces between macromolecular chains of the 
polymer and so the dimension of the polymer molecule was increased (swelling) due to 
polymer relaxation caused by stress of the penetrated solvent.  
 Swelling index was found to increase in the following order, 
HPMC K100M > MC > HPMC E15M&XG > HPMC E15M. 
HPMC K100M and MC showed less swelling index in the beginning but highest 
swelling index was observed (more than 200%) at the end of 12 hours. HPMC E15 
containing tablets showed rapid swelling in the initial hours up to a maximum of 77% but 
could not retain the integrity after 7 hours because of erosion. Formulation F1 showed the 
maximum swelling index of 381.5 % (fig.25) 
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MATRIX INTEGRITY: 32 
       Regarding the matrix integrity studies HPMC K100M and MC containing 
tablets maintained their matrix integrity for more than 24 hours.                                                      
HPMC E15 containing tablets were able to retain the integrity up to 8–10 hours.  
 The results of swelling and matrix integrity studies may be attributed to the fact that 
larger concentration of high viscosity polymer induces the formation of strong viscous gel 
layer that slowed down the rate of hydration of tablet matrix; the process is repeated towards 
new exposed surfaces thus maintaining the matrix integrity. On the contrary, low 
concentration or low viscosity polymer allows rapid hydration, rapid swelling and rapid 
erosion thus low matrix integrity.  
It was also found that reaching maximum swelling would have stretched the gel 
structure so that the bonds responsible for gel structure were broken thus initiating polymer 
erosion32. 
 
IN-VITRO DISSOLUTION STUDIES:  
     The invitro release studies showed that the release profiles of different 
formulations varied according to the type and concentration of polymers.  
     Controlled release profiles were observed in the following order of 80% > 70% > 
60% > 50% > 40% concentrations irrespective of the type of polymer. This may be due to  
the increasing tortuosity and length of the diffusional path through the matrix as the 
polymer content increases 29. 
 Tablets containing HPMC E 15M alone released their whole perindopril content in                 
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6 – 8 hours (F5 – F8) and along with XG (F13 – F16) could be able to control the release up 
to 9 hours. Formulations containing MC showed controlled release up to 10.5 hours (F9) 
while HPMC K100M containing tablets showed controlled release 99.99% up to 11 hours 
(F1) and remained stable.(Table 6A, 6B, 6C, 6D). The results are shown in 
Fig.26,27,28,29&30.  
Results suggested the existence of an inverse correlation between swelling index and 
drug release. The release of the matrix was largely dependent on the polymer swelling, 
drug diffusion and matrix erosion. Among all the formulations F1 (high concentration & 
high viscosity polymer) had the better retardant effect (99.99% in 11 hours) because of the 
formation of strong viscous gel layer that slowed down the rate of diffusion of medium 
into the tablet.  
               
KINETICS OF DRUG RELEASE: 30, 31, 38 
   The kinetic studies of all the formulations showed that zero order plots were fairly 
linear as indicated by their high regression values (Table 7). Therefore it was ascertained that 
the drug release from all the formulations followed zero order kinetics. Further F1 showed 
the closest linearity to unity (r = 0.99) as shown in Fig.31. 
   Fitness of the data to korsemeyer peppas (Fig.32) plots resulted a linear graph with 
regression values close to 1, thus showed that the release of the drug from the matrix 
followed diffusion mechanism.  
In order to find out the exact mechanism of drug release the diffusion exponent                   
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(n value) of korsemeyer peppas model was determined. Formulations F1, F5 and F9 
corresponding to higher concentration (80%)  of HPMC K100 M, HPMC E15, MC            
exhibited Super Case II transport  (n = 1.05, 0.9, 1.04 respectively), a special case of                 
non-Fickian diffusion.  
It was found that the mechanism for all the other formulations was anomalous non 
Fickian diffusion (the release from initially dry, hydrophilic glassy polymers after swelling 
became rubbery). 
 Thus it was evident that as the concentration of polymer was increased the 
mechanism of drug release was shifted from anomalous non Fickian diffusion to Super 
Case II transport because higher polymer content would lead to zero order kinetics.42 
 
DIFFERENTIAL SCANNING CALORIMETRY: 32
 
The DSC thermo grams of pure drug and the different polymers were shown in the 
Fig. An endothermic peak corresponding to the melting point of pure drug was prominent in 
all the drug polymer mixture, which suggested clearly that there was no interaction between 
the drug and the polymers and the drug was existed in its unchanged form. 
FT-IR STUDIES: 39 
             FT-IR spectrum of the drug and polymers are shown in the fig. The spectrum of the 
drug had characteristic peaks of C-H stretching (VF 2929, 2848, 2750), C=O stretching                
(VF 2640&1739 cm-1), hydrogen bonded acids (VF 2551.61 cm-1), C-H bending                    
(VF 1392 cm-1), OH bending (VF 1315, 1292, 1205 cm-1), aromatic rings (VF 1566 cm-1),            
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C-H rocking (939, 750, 703, 475 cm-1) thus indicating the identity and purity of the drug. 
All those characteristic peaks were also found in the spectrum of drug and polymer 
combinations and there was no change in the existing peaks.. This clearly indicated that there 
was no interaction between the drug and the polymer and the drug was present in its 
unchanged form.    
SELECTION OF BEST FORMULATION: 
From the above results of characterization F1 was selected the best formulation 
because, 
 Invitro release profile   :   99.99% in 11 hours 
 Release kinetics              :   closest linearity to zero order kinetics(fig: 
 Swelling Index              :   381.5% 
 Floating lag time            :   0 seconds 
 
The selected best formulation F1 was subjected to, 
• Comparison with marketed formulation  
• Effect of diluents 
• Stability studies 
• Invivo studies 
COMPARISON WITH MARKETED FORMULATION: 
             The release of the best formulation was found to be 99.99% in 11 hours when 
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compared to the marketed formulation whose release was 99.98% within 1 hour. Thus the 
formulation F1 showed controlled release profile than the marketed conventional tablet. The 
results are shown in the fig.33 
EFFECT OF DILUENTS ON THE RELEASE OF BEST FORMULATION: 
      The tablets were prepared by replacing lactose with dicalcium phosphate (of the 
best formulation). The tablets were elegant in appearance and floated immediately. The  in 
vitro release studies showed that the drug release was prolonged up to 12 hours (99.97%) in 
the presence of DCP, while lactose containing formulation showed controlled release of 
99.99% in 11 hours. The results revealed that insoluble diluents such as DCP could retard 
the drug release when compared to the soluble diluents such as lactose. The results are shown 
in the fig.34. 
STABILITY STUDIES: 
Optimized formulation F1 was subjected to stability studies at 40°C at 75% RH. The 
results showed no significant change in the physical appearance, and in vitro release studies 
during storage. Thus it was found that the gastro retentive floating tablets of perindopril 
erbumine were stable under these storage conditions. The results are shown in the table 8. 
IN-VIVO X-RAY STUDIES: 
The Barium sulphate containing floating tablets floated immediately showed hardness 
of 4 kg/cm3 and thickness 3mm. The in-vivo floating behavior of the tablet was assessed by 
X-ray image studies in rabbits.  Gastric radiography was done in the abdominal region at 
periodic time intervals using the X-ray machine.   
 Both the tablets were clearly seen in the GIT at different positions on the upper part 
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of the stomach confirmed its in-vivo floating behavior. Also the swelling of the tablet can be 
visualized from the increase in the size of tablets in the images taken at 2nd hour, 4th hour and 
8th hour. Both the tablets retained the matrix integrity up to 12 hours. Gastric residence time 
was found to be more than 12 hours. Thus it was evident that the formulation could be 
retained in the gastric region to ensure complete release of drug. 
The X-Ray photo graphs are shown in Fig.35. 
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CHAPTER - 11 
SUMMARY AND CONCLUSION 
 The present investigation was to develop floating dosage forms of perindopril 
erbumine by non-effervescent technique using different concentrations of gel 
forming hydrophilic polymers. 
 Formulations containing HPMC K100M and MC floated more than 12 hours, but in 
the case of HPMC E15 (alone or along with XG) the formulations floated for 8 - 10 
hours followed by erosion. 
 Swelling index was found to increase in the following order, 
                       HPMC K100M > MC > HPMC E15M & XG > HPMC E15M. 
 
 Larger concentration of high viscosity polymer induces the formation of strong 
viscous gel layer that slowed down the rate of hydration of tablet matrix while low 
concentration or low viscosity polymer allows rapid hydration, rapid swelling and 
rapid erosion thus low matrix integrity.  
 The release of the matrix was largely dependent on the polymer swelling, drug 
diffusion and matrix erosion. Among all the formulations F1 (high concentration & 
high viscosity polymer) had the better retardant effect (99.99% in 11 hours)  
 Fitness of the data to korsemeyer peppas plots resulted a linear graph with regression 
values close to 1, thus showed that the release of the drug from the matrix followed 
diffusion mechanism. 
 It was evident that as the concentration of polymer was increased the mechanism of 
drug release was shifted from anomalous non Fickian diffusion to Super Case II 
transport. 
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 The selected formulation F1 was found to be stable under the storage conditions and it 
exhibited gastric residence of more than 12 hours in invivo studies. 
 The results showed that insoluble diluents such as DCP could retard the drug release 
when compared to the soluble diluents such as Lactose. 
 The invivo x-ray studies showed that the best formulation had gastric residence time 
of more than 12 hours. 
 The selected formulation was stable under the conditions of 40°C at 75% RH. 
 The FT-IR and DSC studies revealed that there was no interaction between the drug 
and the polymers. 
CONCLUSION: 
                  It was concluded that an inverse correlation existed between swelling 
index and the drug release i.e. the formulation having maximum swelling index 
showed better controlled release. The formulations containing HPMC K100M 
showed satisfactory results for floating and swelling behaviour as well as 
controlled release properties. In the best formulation (F1) swelling was strong 
enough to avoid premature disintegration as well as the burst effect and retarded 
drug release in a controlled manner for a longer period of time (11 hours) and 12 
hour gastric residence was confirmed by invivo studies. Thus floating drug 
delivery system using high viscosity gel forming polymers would be a promising 
and feasible approach to achieve controlled release above the absorption zone 
especially for narrow absorption window drugs like Perindopril erbumine. It is 
the role of the future scientists to utilize the effectiveness of this delivery system 
clinically for hypertensive patients.  
DSC THERMOGRAMS OF DRUG AND POLYMERS 
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A) DRUG   B)HPMC K100M   C)HPMC E15   D)MC   E)XG                               
F)DRUG+HPMC K100M   G)  DRUG+HPMC E15   H)DRUG+MC    
I)DRUG+XG+XG 
Table 1 
  Calibration of Perindopril erbumine 
 
 
Medium : 0.1M HCL  
λ max  : 208 nm 
 
S. No. CONCENTRATION  
(µg/ml) 
ABSORBANCE 
* 
STANDARD DEVIATION  
*  (± S.D) 
1 5 0.115 0.0001 
2 10 0.230 0.0008 
3 15 0.346 0.0004 
4 20 0.459 0.0023 
5 25 0.573 0.0003 
6 30 0.689 0.0022 
7 35 0.804 0.0008 
8 40 0.919 0.0010 
9 45 1.033 0.0005 
10 50 1.151 0.0025 
 
* Average of three trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
       
 Table 2 
 Formulation of Non-Effervescent Floating Tablets 
 
 
 
 
Ingredients 
Quantity (mg) for 1 tablet (total weight 150mg) 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 
Perindopril 
erbumine 
8 8 8 8 8 8 8 8 
Hydro colloid 
Polymer 
120 105 90 75 120 105 90 75 
Lactose 19 34 49 64 19 34 49 64 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Magnesium 
Stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Ingredients 
Quantity (mg) for 1 tablet 
F-9 F-10 F-11 F-12 F-13 F-14 F-15 F-16 
Perindopril 
erbumine 
8 8 8 8 8 8 8 8 
Hydro colloid 
Polymer 
105 90 75 60 105 90 90 75 
Xanthan Gum - - - - 15 30 15 30 
Lactose 34 49 64 79 19 19 34 34 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Magnesium 
Stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3 
  Preformulation Studies for the Granules of  
Non-Effervescent Tablets 
 
 
Code 
No. 
Bulk 
Density 
g / cc * 
Tapped 
Density 
g / cc * 
Compressibility 
Index (%) * 
Angle of 
Repose 
(θ) * 
% Yield of 
granules 
F1 0.41 0.52 21 26.56 96.47 
F2 0.39 0.51 23.5 27.15 99.21 
F3 0.42 0.52 19 26.81 96.82 
F4 0.38 0.53 24 27.67 98.21 
F5 0.41 0.50 18 27.02 97.25 
F6 0.42 0.51 18 26.56 96.86 
F7 0.39 0.51 23.5 25.78 99.21 
F8 0.42 0.51 18 24.56 96.82 
F9 0.40 0.52 23 27.29 99.21 
F10 0.38 0.51 22.4 28.32 99.23 
F11 0.41 0.52 21.1 29.20 97.64 
F12 0.39 0.51 23.4 26.40 98.82 
F13 0.42 0.52 19.2 26.22 99.21 
F14 0.41 0.51 19.6 25.12 98.82 
F15 0.40 0.51 21.5 25.27 99.61 
F16 0.41 0.51 19.6 24.81 98.82 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 4 
 Post Compression Evaluation of Non-effervescent Floating Tablets 
 
 
 
Code 
No. 
Hardness 
(kg/cm3)*  
 
Thickness 
(mm)* 
 
Diameter 
(mm)* 
% Friability * Average Weight  
(mg ±7.5 %) 
% Drug 
Content 
F1 3.5 – 4 
 
3 8 0.53 149.6 99.21 
F2 3.5 – 4 3 8 0.43 150.4 100.7 
F3 3.5 – 4 
 
2.8 8 0.61 151.6 98.64 
F4 3.5 – 4 
 
2.9 8 0.59 151.8 98.28 
F5 3.5 – 4 
 
3 8 0.9 150.3 98.64 
F6 3.5 – 4 
 
2.9 8 0.8 147.1 98.43 
F7 3.5 – 4 3 8 0.71 147.5 99.21 
F8 3.5 – 4 
 
2.8 8 0.51 155.5 98.96 
F9 3.5 – 4 
 
2.8 8 0.2 152.7 99.6 
F10 3.5 – 4 
 
3 8 0.39 151.5 98.43 
F11 3.5 – 4 
 
2.9 8 0.72 150.3 98.82 
F12 3.5 – 4 
 
3 8 0.61 151.2 99.21 
F13 3.5 – 4 
 
2.8 8 0.1 157.7 99.6 
F14 3.5 – 4 
 
2.9 8 0.6 150.6 99.26 
F15 3.5 – 4 
 
3 8 0.7 153.4 99.21 
F16 3.5 – 4 
 
3 8 0.6 155.6 99.21 
 
 
 
 
 
 
  
 
 
Table 5 
  Evaluation of Non-effervescent Floating Tablets 
 
Formulation Buoyancy lag time * Total Floating Time 
(hrs)* 
Swelling Index 
F1 Float immediately 
 
> 24 hrs 381.5 
F2 Float immediately 
 
> 24 hrs 362.7 
F3 2 minutes 25 seconds 
 
> 24 hrs 342.3 
F4 3 minutes 50 seconds 
 
> 24 hrs 335.1 
F5 3 minutes 20 seconds 
 
> 8 hrs 76.5 
F6 3 minutes 50 seconds 
 
> 8 hrs 61.2 
F7 4 minutes 10 seconds 
 
> 8 hrs 59.8 
F8 4 minutes 25 seconds 
 
> 8 hrs 57.4 
F9 6 minutes 5 seconds 
 
> 24 hrs 274.3 
F10 7 minutes 10 seconds 
 
> 24 hrs 256.4 
F11 8 minutes 5 seconds 
 
> 24 hrs 238.6 
F12 8 minutes 8 seconds 
 
> 24 hrs 225.4 
F13 7 minutes 10 seconds 
 
> 10 hrs 62.7 
F14 8 minutes 30 seconds 
 
> 10 hrs 68.8 
F15 8 minutes 45 seconds 
 
> 10 hrs 62.7 
F16 8 minutes 50 seconds 
 
> 10 hrs 77.2 
 
 
 
 
 
 
  
 
 
In-Vitro Release Data of Non-Effervescent Floating Tablets 
 
Table: 6 A 
 
 
S. No. 
 
Time 
(hrs) 
Cumulative Percentage of Drug Release * 
F-1 F-2            F-3 F-4 
 K100M-80% K100M-70% K100M-60% K100M-50% 
1. 0.15 0.13 ± 0.08 3.23 ± 0.13 5.74 ± 0.63 8.52 ± 0.60 
2. 0.30 3.25 ± 0.22 7.77 ± 0.29 7.11 ± 0.24 17.10 ± 0.24 
3. 0.45 7.34 ± 0.17 10.67 ± 0.45 17.40 ± 0.42 21.35 ± 0.29 
4. 1.00 9.34 ± 0.04 14.10 ± 0.70 21.50 ± 0.09 24.75 ± 0.15 
5. 1.30 14.10 ± 0.46 17.62 ± 2.05 25.87 ± 0.17 28.06 ± 0.42 
6. 2.00 22.84 ± 0.18 25.23 ± 3.09 29.40 ± 0.17 31.28 ± 0.33 
7. 2.30 24.87 ± 0.44 27.31 ± 1.75 34.77 ± 0.17 38.60 ± 0.22 
8. 3.00 28.89 ± 0.18 32.38 ± 0.43 41.50 ± 0.17 45.70 ± 0.13 
9. 3.30 34.56 ± 0.35 36.17 ± 0.45 52.90 ± 2.74 59.60 ± 0.37 
10. 4.00 38.65 ± 1.01 41.20 ± 3.24 65.40 ± 0.58 68.80 ± 0.21 
11. 4.30 44.60 ± 0.27 47.60 ± 2.58 69.80 ± 0.82 73.70 ± 0.24 
12. 5.00 49.45 ± 0.29 52.90 ± 0.73 74.70 ± 0.25 79.80 ± 0.58 
13. 5.30 53.50 ± 0.17 57.70 ± 0.78 83.50 ± 0.78 87.80 ± 0.17 
14. 6.00 59.61 ± 0.22 63.80 ± 0.45 88.60 ± 5.58 90.70 ± 3.45 
15. 6.30 63.15 ± 0.25 67.90 ± 0.99 92.60 ± 0.21 96.20 ± 3.44 
16. 7.00 66.95 ± 0.27 73.80 ± 0.59 94.60 ± 0.39 98.10 ± 0.93 
17. 7.30 70.57 ± 1.21 76.70 ± 1.04 97.50 ± 0.24 100.00 ± 0.27 
18. 8.00 71.76 ± 1.47 79.80 ± 0.39 100.20 ± 0.45 98.68 ± 0.17 
19. 8.30 75.48 ± 1.82 84.60 ± 1.00 99.36 ± 0.62 98.15 ± 0.50 
20. 9.00 80.10 ± 0.25 88.90 ± 0.86 98.82 ± 0.38 98.02 ± 0.70 
21. 9.30 84.10 ± 0.04 96.80 ± 0.93 96.22 ± 2.89      98.01 ± 1.30 
22. 10.00 90.98 ± 0.22 100.31 ± 0.21 95.62 ± 2.23      97.92 ± 0.87 
23. 10.30 97.39 ± 0.61 99.81 ± 0.34 94.88 ± 1.75 97.66 ± 0.83 
24. 11.00 99.99 ± 0.94 97.04 ± 3.23 94.53 ± 1.10      97.18 ± 1.50 
25. 12.00 97.87 ± 3.77 96.79 ± 3.47 93.98 ± 1.39 97.07 ± 1.60 
  
 
 
 
Table: 6 B 
 
 
 
 
S. No. 
 
Time 
(hrs) 
Cumulative Percentage of Drug Release * 
F-5 F-6 F-7 F-8 
HPMC E15 80% HPMC E15 70% HPMC E15 60% HPMC E15 50% 
1. 0.15 1.6 ± 0.14 3.4 ± 0.30 2.21 ± 0.41 4.6 ± 1.40 
2. 0.30 7.7 ± 0.15 8.8 ± 0.40 10.06 ± 0.20 13.5 ± 0.30 
3. 0.45 12.9 ± 0.24 15.7 ± 0.70 15.1 ± 0.90 18.9 ± 0.14 
4. 1.00 22.5 ± 0.43 25.6 ± 0.40 22.3 ± 0.34 26.7 ± 0.58 
5. 1.30 25.9 ± 0.16 29.1 ± 1.30 35.2 ± 0.51 38.9 ± 0.40 
6. 2.00 31.8 ± 0.47 35.6 ± 0.40 38.33 ± 0.15 42.8 ± 2.21 
7. 2.30 33.2 ± 0.46 38.1 ± 0.30 45.3 ± 0.13 49.8 ± 0.40 
8. 3.00 39.3 ± 0.54 45.1 ± 0.30 50.1 ± 0.29 59.4 ± 2.45 
9. 3.30 45.1 ± 0.33 48.9 ± 0.40 52.3 ± 0.77 62.8 ± 3.16 
10. 4.00 49.9 ± 0.25 53.6 ± 0.40 60.6 ± 0.30 68.4 ± 0.82 
11. 4.30 53.7 ± 0.19 59.5 ± 0.20 68.7 ± 0.20 78.7 ± 4.10 
12. 5.00 57.9 ± 0.34 65.7 ± 0.30 78.7 ± 0.40 85.6 ± 4.50 
13. 5.30 63.8 ± 2.70 71.1 ± 3.10 90.8 ± 0.22 93.6 ± 3.50 
14. 6.00 68.5 ± 1.10 76.3 ± 3.50 96.3 ± 0.14 100.1 ± 2.50 
15. 6.30 75.8 ± 3.30 78.4 ± 2.70 100 ± 0.60 98.3 ± 0.50 
16. 7.00 80.2 ± 0.50 85.7 ± 1.70 96.9 ± 0.60 98.23 ± 0.60 
17. 7.30 89.2 ± 0.30 95.7 ± 0.30 96.6 ± 0.50 98.12 ± 0.70 
18. 8.00 96.5 ± 0.20 100.3 ± 0.80 95.99 ± 0.40 98.05 ± 0.95 
19. 8.30 100.6 ± 0.20 99.1 ± 0.60 94.78 ± 0.30 97.96 ± 0.30 
20. 9.00 98.68 ± 0.22 98.1 ± 0.70 94.3 ± 0.30 97.89 ± 0.45 
21. 9.30 98.5 ± 0.64 97.7 ± 0.40 94 ± 0.20 97.88 ± 0.70 
22. 10.00 98.4 ± 0.76 96.9 ± 0.60 93.04 ± 0.60 97.7 ± 0.60 
23. 10.30 98.4 ± 0.88 95.8 ± 0.60 90.65 ± 3.35 97.2 ± 0.03 
24. 11.00 97.6 ± 0.14 94.6 ± 0.70 89.88 ± 3.10 97.15 ± 0.73 
25. 12.00 97.4 ± 0.48 93.8 ± 0.70 89.76 ± 3.42 97.01 ± 0.60 
 
* Average of three trials 
 
 
Table: 6 C 
 
 
S. No. 
 
Time 
(hrs) 
Cumulative Percentage of Drug Release * 
           F-9 F-10 F-11 F-12 
MC 70% MC 60% MC 50% MC 40% 
1. 0.15 1.21 ± 0.40 3.30  ± 0.50 3.15 ± 0.50 3.15 ± 0.14 
2. 0.30 3.6 ± 0.17 6.50 ± 0.40 10.63 ± 4.50 16.68 ± 0.28 
3. 0.45 7.5 ± 0.19 9.43 ± 0.20 16.84 ± 4.90 26.11 ± 2.56 
4. 1.00 10.43 ± 0.17 14.12 ± 1.60 23.43 ± 4.80 29.78 ± 0.40 
5. 1.30 16.1 ± 0.33 20.13 ± 0.18 31.8 ± 0.40 34.11 ± 0.33 
6. 2.00 22.66 ± 0.19 24.80 ± 0.10 35.5 ± 0.20 37.31 ± 0.38 
7. 2.30 25.75 ± 0.01 31.70 ± 0.13 38.4 ± 0.22 41.71 ± 0.38 
8. 3.00 27.72 ± 0.94 37.73 ± 0.25 40.6 ± 1.16 42.93 ± 0.20 
9. 3.30 29.48 ± 0.47 41.00 ± 0.47 44.3 ± 1.25 47.28 ± 3.10 
10. 4.00 32.22 ± 0.19 44.44 ± 0.17 48.8 ± 0.58 52.46 ± 2.70 
11. 4.30 37.67 ± 0.17 45.7 ± 0.33 55.7 ± 1.39 57.92 ± 0.30 
12. 5.00 44.65 ± 0.19 49.4 ± 0.50 59.6 ± 0.40 63.03 ± 4.80 
13. 5.30 47.7 ± 0.17 54.7 ± 0.30 65.32 ± 4.40 69.91 ± 0.41 
14. 6.00 56.76 ± 0.90 60.94 ± 1.30 69.18 ± 3.30 76.6 ± 0.19 
15. 6.30 61.68 ± 0.54 66.82 ± 0.50 74.46 ± 0.41 93.8 ± 0.41 
16. 7.00 67.58 ± 0.85 73.5 ± 0.33 88.54 ± 0.26 97.3 ± 0.37 
17. 7.30 72.84 ± 0.19 79.1 ± 0.17 89.98 ± 0.49 99.99 ± 0.19 
18. 8.00 76.39 ± 3.10 85.73 ± 0.24 95.96 ± 0.17 99.3 ± 0.14 
19. 8.30 76.45 ± 0.90 90.23 ± 0.73 100.35 ± 2.70 98.8 ± 0.29 
20. 9.00 85.73 ± 0.60 98.94 ± 1.70 99.66 ± 0.51 98.7 ± 0.30 
21. 9.30 90.03 ± 0.90 100.39 ± 0.24 98.45 ± 1.20 98.3 ± 0.50 
22. 10.00 100.62 ± 0.15 99.59 ± 0.33 97.58 ± 1.40 97.7 ± 0.40 
23. 10.30 100.07 ± 0.17 98.85 ± 0.45 96.94 ± 1.20 95.9 ± 0.20 
24. 11.00 99.44 ± 0.18 98.12 ± 0.25 96.1 ± 0.70 95.8 ± 0.20 
25. 12.00 98.21 ± 0.80 97.61 ± 0.00 94.91 ± 0.50 95.5 ± 0.20 
 
* Average of three trials 
 
  
 
 
Table: 6 D 
 
 
S. No. 
 
Time 
(hrs) 
Cumulative Percentage of Drug Release * 
F-13 F-14 F-15 F-16 
E15 70% & 
XG 10% 
E15 60% & 
XG20% 
E1560% & 
XG10% 
E15 50% & 
XG20% 
1. 0.15 1.2 ± 0.00 3.2 ± 0.50 4.6 ± 0.10 6.4 ± 0.28 
2. 0.30 5.9 ± 0.30 7.3 ± 0.40 8.6 ± 0.20  10.4 ± 0.40 
3. 0.45 10.5 ± 0.40 12.4 ± 1.50 12.4 ± 0.30 13.4 ± 0.40 
4. 1.00 15.2 ± 0.40 15.5 ± 0.50 16.4 ± 0.70 17.7 ± 0.30 
5. 1.30 18.9 ± 0.50 22.5 ± 1.50 24.5 ± 0.40 25.6 ± 0.30 
6. 2.00 25.3 ± 0.40 26.6 ± 0.30 28.5 ± 0.50 34.02 ± 0.33 
7. 2.30 35.2 ± 0.50 36.5 ± 1.90 37.6 ± 0.20 39.5 ± 0.30 
8. 3.00 38.5 ± 0.00 41.3 ± 0.50 42.5 ± 0.30 44.3 ± 0.20 
9. 3.30 41.1 ± 0.30 43.6 ± 2.30 45.9 ± 0.01 47.6 ± 0.20 
10. 4.00 44.7 ± 0.30 46.2 ± 1.90 49.5 ± 0.20 55.6 ± 0.20 
11. 4.30 45.9 ± 0.30 49.9 ± 0.50 54.7 ± 1.20 58.7 ± 0.90 
12. 5.00 51.2 ± 0.40 55.4 ± 0.70 62.7 ± 1.70 65.4 ± 0.30 
13. 5.30 56.1 ± 0.80 61.9 ± 0.30 68.7 ± 0.90 72.9 ± 1.90 
14. 6.00 62.2 ± 0.40 71.3 ±0.80 75.8 ± 0.40 77.9 ± 3.00 
15. 6.30 68.9 ± 0.30 74.6 ± 0.20 81.9 ± 0.10 83.1 ± 3.70 
16. 7.00 76.9 ± 1.90 79.7 ± 0.60 86.4 ± 0.04 88.6 ± 4.10 
17. 7.30 79.9 ± 0.90 82.9 ± 0.10 91.6 ± 0.40 95.6 ± 0.30 
18. 8.00 87.7 ± 0.90 88.5 ± 0.20 98.9 ±  1.10 100.5 ± 0.50 
19. 8.30 91.7 ± 1.80 93.8 ± 1.60 100.2 ± 0.30 100.1 ± 0.20 
20. 9.00 97.6 ± 0.50 100.7 ± 1.10 100.1 ± 0.50 99.6 ± 1.00 
21. 9.30 100.4 ± 0.30 99.3 ± 1.60 98.8 ± 0.60 98.6 ± 0.20 
22. 10.00 98.2 ± 0.30 99.2 ± 1.10 98.3 ± 0.40 98.1 ± 0.30 
23. 10.30 97.4 ± 0.50 98.7 ± 0.90 98.1 ± 0.50 98.1 ± 0.10 
24. 11.00 95.9 ± 0.50 97.9 ± 1.30 95.9 ± 0.04 96.4 ± 0.10 
25. 12.00 95.1 ± 0.20 96.7 ± 1.80 94.5 ± 1.40 95.9 ± 0.30 
* Average of three trials 
Table 7 
 
RELEASE KINETICS OF ALL THE FORMULATIONS 
 
 
Formulations 
Zero order 
kinetics 
 
 
First order 
kinetics 
Higuchi 
model 
Korsemeyer 
peppas 
model 
Hixon Crovel 
model 
r2 k r2 k r2 
 
k 
 
r2 k r2 k 
F1 0.99 8.82 0.72 0.11 0.93 32.8 0.98 1.05 0.86 0.29 
F2 0.98 9.03 0.72 0.11 0.92 33.2 0.98 0.85 0.87 0.33 
F3 0.85 8.82 0.61 0.11 0.93 35.4 0.99 0.78 0.82 0.34 
F4 0.85 8.59 0.73 0.07 0.93 34.7 0.99 0.65 0.81 0.34 
F5 0.94 9.08 0.66 0.09 0.94 35.1 0.95 0.96 0.88 0.35 
F6 0.91 8.67 0.68 0.08 0.95 34.3 0.98 0.79 0.78 0.33 
F7 0.79 8.18 0.56 0.08 0.91 33.9 0.95 0.83 0.67 0.27 
F8 0.79 8.25 0.59 0.07 0.94 34.5 0.98 0.73 0.78 0.33 
F9 0.98 8.56 0.74 0.13 0.98 34.5 0.98 1.04 0.84 0.35 
F10 0.98 9.21 0.72 0.11 0.92 34.7 0.93 0.87 0.88 0.36 
F11 0.93 8.74 0.62 0.11 0.95 34.1 0.97 0.74 0.82 0.34 
F12 0.89 8.51 0.55 0.09 0.94 33.7 0.95 0.72 0.85 0.33 
F13 0.92 8.97 0.68 0.10 0.94 35.2 0.98 0.76 0.83 0.36 
F14 0.92 9.11 0.75 0.089 0.94 35.48 0.99 0.81 0.82 0.36 
F15 0.96 9.12 0.75 0.09 0.94 34.93 0.98 0.85 0.89 0.34 
F16 0.96 9.11 0.70 0.10 0.93 34.58 0.95 0.98 0.86 0.33 
 
 
 
 Table: 8 
 
 
STABILITY STUDIES REPORT 
 
F1 (HPMC 80 %) 
 
Temperature:  400C + 20C and RH of 75 % + 2 % 
 
 
Intervals of 
Testing 
Appearance Hardness 
(4-4.5 kg / cm2) 
Floating Lag Time 
(< 1 min) 
Drug Content 
(90- 110 %) 
0 day White colour, 
circular, biconvex 
tablets 
4 kg / cm2 Float immediately 100.5 
15 days White colour, 
circular, biconvex 
tablets 
4 kg / cm2 Float immediately 99.61 
30 days White colour, 
circular, biconvex 
tablets 
4 kg / cm2 Float immediately 101.87 
45 days White colour, 
circular, biconvex 
tablets 
4 kg / cm2 Float immediately 100.93 
60 days White colour, 
circular, biconvex 
tablets 
4 kg / cm2 Float immediately 100.86 
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